<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>c90746exv2w1.htm
<DESCRIPTION>EXHIBIT 2.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 2.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">
<DIV align="right" style="font-size: 10pt; margin-top: 10pt"><B>Exhibit&nbsp;2.1</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">
 [*]  Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.
</div>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>STOCK PURCHASE AGREEMENT</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 10pt">by and between

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 10pt"><B>QLT INC.</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 10pt">and

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 10pt"><B>TOLMAR HOLDING, INC.</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 10pt">Dated as of October&nbsp;1, 2009

</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><u> <B>TABLE OF CONTENTS </B></u>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="77%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE I DEFINITIONS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">1.1 Definitions</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">1.2 Other Definitional Provisions</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE II ASSETS AND LIABILITIES OF QLT USA; PURCHASE AND SALE OF SHARES</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">2.1 Assets and Liabilities of QLT USA</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">2.2 Purchase and Sale of Shares; Purchase Price</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE III CLOSING</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">3.1 Closing</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">3.2 Deliveries on the Closing Date and after the Closing</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">3.3 Post-Closing Deliveries</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE IV REPRESENTATIONS AND WARRANTIES REGARDING QLT USA</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">4.1 Organization; Corporate Records</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">4.2 No Conflicts</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">4.3 Capitalization</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">4.4 Title</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">4.5 No Subsidiaries</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">4.6 Intellectual Property</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">4.7 Litigation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">4.8 Taxes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">4.9 Compliance with Laws; Regulatory Matters</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">4.10 Material Contracts</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">4.11 Financial Statements</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">4.12 No Undisclosed Liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">4.13 Employee Benefit and Other Employment Matters</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">4.14 Insurance</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">4.15 Related Party Transactions</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">4.16 Real Property</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE V REPRESENTATIONS AND WARRANTIES OF SELLER</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">5.1 Organization; Due Authorization</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">5.2 No Conflicts; Enforceability</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">5.3 Consents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">5.4 Litigation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">5.5 Brokers&#146; Fees</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">5.6 Shares</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">5.7 No Other Representations or Warranties</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">[*] Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->i<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="77%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE VI REPRESENTATIONS AND WARRANTIES OF PURCHASER</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.1 Organization; Due Authorization</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.2 No Conflicts; Enforceability</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.3 Consents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.4 Litigation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.5 Solvency</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.6 Securities Act</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.7 No Other Representations or Warranties</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE VII COVENANTS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">27</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">7.1 Conduct of the Business Post-Closing</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">27</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">7.2 Required Approvals and Consents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">27</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">7.3 Further Assurances; Further Documents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">28</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">7.4 Noncompetition</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">28</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">7.5 HSR Fees</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">29</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">7.6 Product Reports</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">29</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">7.7 Name Change</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">29</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE VIII CONDITIONS TO CLOSING</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">29</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">8.1 Conditions Precedent to Obligations of Purchaser and Seller</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">29</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE IX ADDITIONAL COVENANTS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">30</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">9.1 Confidentiality; Publicity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">30</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">9.2 Availability of Records</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">30</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">9.3 Regulatory Matters</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">9.4 Tax Matters</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE X TERMINATION</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">32</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">10.1 Termination</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">32</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">10.2 Automatic Termination</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">32</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">10.3 Consequences of Termination</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">32</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE XI SURVIVAL; INDEMNIFICATION</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">33</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">11.1 Survival of Representations and Warranties and Covenants</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">33</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">11.2 Indemnification</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">33</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">11.3 Notice of Claims</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">34</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">11.4 Third Person Claims</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">35</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">11.5 Limitation on Indemnity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">36</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">11.6 Remedies</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">36</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">11.7 Limitation on Liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">37</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">11.8 Knowledge</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">37</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">11.9 No Set-off</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">37</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">11.10 Treatment of Indemnification Payments</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">37</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">[*] Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->ii<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="77%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE XII MISCELLANEOUS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">37</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">12.1 Assignment; Binding Effect</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">37</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">12.2 Expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">38</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">12.3 Notices</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">38</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">12.4 Severability</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">39</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">12.5 Entire Agreement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">39</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">12.6 No Third Party Beneficiaries</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">39</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">12.7 Waiver</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">39</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">12.8 Governing Law; Arbitration</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">39</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">12.9 Waiver of Jury Trial</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">39</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">12.10 Injunctive Relief</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">39</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">12.11 Headings</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">40</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">12.12 Counterparts</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">40</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">12.13 Schedules</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">40</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">12.14 Construction</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">40</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">12.15 Time of the Essence</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">40</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">[*] Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->iii<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>STOCK PURCHASE AGREEMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"><B>THIS STOCK PURCHASE AGREEMENT </B>(this &#147;<U>Agreement</U>&#148;), dated as of October&nbsp;1, 2009 (the
&#147;<U>Execution Date</U>&#148;), is entered into by and between QLT Inc., a corporation formed under the
laws of the Province of British Columbia, Canada (&#147;<U>Seller</U>&#148;), and TOLMAR Holding, Inc., a
Delaware corporation (&#147;<U>Purchaser</U>&#148;). Each of Seller and Purchaser is sometimes referred to
herein, individually, as a &#147;<U>Party</U>&#148; and, collectively, as the &#147;<U>Parties</U>.&#148; All
capitalized terms used herein shall have the meanings specified in <U>ARTICLE I</U> below or
elsewhere in this Agreement, as applicable.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>INTRODUCTION</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">WHEREAS, Seller owns 100% of the issued and outstanding shares of capital stock of QLT USA,
Inc., a Delaware corporation (&#147;<U>QLT USA</U>&#148;); and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">WHEREAS, Seller desires to sell and Purchaser desires to purchase 100% of the issued and
outstanding shares of capital stock of QLT USA.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">NOW, THEREFORE, in consideration of the foregoing and the representations, warranties,
covenants, agreements and provisions set forth herein, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be
legally bound hereby, the Parties agree as follows:
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>ARTICLE I<BR>
DEFINITIONS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">1.1 <U>Definitions</U>. In addition to the terms defined elsewhere in this Agreement, the
following terms shall have the meanings set forth below for purposes of this Agreement:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">&#147;<U>10% Indemnity Cap</U>&#148; has the meaning set forth in <U>Section&nbsp;11.5</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">&#147;<U>15% Indemnity Cap</U>&#148; has the meaning set forth in <U>Section&nbsp;11.5</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">&#147;<U>AAA</U>&#148; has the meaning set forth in <U>Section&nbsp;11.3(c)</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Act</U>&#148; means the United States Federal Food, Drug, and Cosmetic Act of 1938, as
amended, and the rules, regulations and guidance documents promulgated thereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Action</U>&#148; means any claim, action, suit, arbitration, inquiry, hearing, audit,
proceeding or investigation by or before any Governmental Authority or arbitrator.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Affiliate</U>&#148; means, with respect to any specified Person, any other Person directly or
indirectly controlling or controlled by, or under direct or indirect common control with, such
specified Person. For purposes of this definition, (a) &#147;control&#148; when used with respect to any
specified Person means the power to direct the management and policies of such specified Person,
directly or indirectly, whether through ownership of voting securities, by contract or otherwise
and the words &#147;controlling&#148; and &#147;controlled&#148; have meanings correlative to the word &#147;control&#148; and
(b)&nbsp;a specified Person shall be deemed, in any event, to control any other Person if such specified
Person is the beneficial owner (as defined in Rule&nbsp;13d-3 of the Exchange Act) of more than 50% of
the voting securities, voting ownership interests or voting partnership interests of such other
Person.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">[*] Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.
</DIV>

<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Affiliate Resolution Agreement</U>&#148; means the Affiliate Resolution Agreement by and among
Purchaser, Seller and QLT USA, dated of even date herewith.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">&#147;<U>Agreement</U>&#148; has the meaning set forth in the first paragraph of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Applicable Permits</U>&#148; means the permits, approvals, licenses, franchises or
authorizations, including the Registrations, from any Governmental Authority held by QLT USA set
forth on <U>Schedule&nbsp;1.1(a)</U> hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Assets</U>&#148; of any Person means all assets and properties of any kind, nature, character
and description (whether real, personal or mixed, whether tangible or intangible, whether absolute,
accrued, contingent, fixed or otherwise and wherever situated), including the goodwill related
thereto, operated, owned or leased by such Person, including cash, cash equivalents, accounts and
notes receivable, chattel paper, documents, instruments, pre-paid expenses and other assets,
general intangibles, equipment, inventory, goods and Intellectual Property.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Atrigel<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></U>&#148; means the drug delivery system consisting of flowable compositions (e.g.,
solutions, gels, pastes and putties) of biodegradable polymers and biocompatible solvents.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Atrigel License Agreement</U>&#148; means the Exclusive License Agreement between QLT USA,
Inc. and Reckitt Benckiser Pharmaceuticals Inc., dated August&nbsp;25, 2008.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">&#147;<U>Atrix Acquisition Date</U>&#148; means November&nbsp;20, 2004.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">&#147;<U>Audited Financial Statements</U>&#148; has the meaning set forth in <U>Section&nbsp;4.11(a)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">&#147;<U>August Balance Sheet</U>&#148; has the meaning set forth in <U>Section&nbsp;4.11(c)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">&#147;<U>Basket Amount</U>&#148; has the meaning set forth in <U>Section&nbsp;11.5</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Business Day</U>&#148; means any day, other than a Saturday, a Sunday or a day on which
commercial banks in New York, New York, United States of America are authorized or obligated by Law
to be closed.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">&#147;<U>Bylaws</U>&#148; means the bylaws of QLT USA, as amended through the date hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Cash Equivalents</U>&#148; means securities issued or directly and fully guaranteed or insured
by, or certificates of deposit with, the Goldman Sachs Financial Square Government Fund.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Certificate of Incorporation</U>&#148; means the certificate of incorporation of QLT USA, as
amended through the date hereof.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">&#147;<U>Claim Notice</U>&#148; has the meaning set forth in <U>Section&nbsp;11.3(a)</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Closing</U>&#148; means the closing of the purchase and sale of the Shares contemplated by
this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">&#147;<U>Closing Date</U>&#148; has the meaning set forth in <U>Section&nbsp;3.1</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Closing Date Balance Sheet</U>&#148; means the consolidated balance sheet of QLT USA as of the
close of business on the day immediately preceding the Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">[*] Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.
</DIV>

<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Closing Date Financial Statement</U>&#148; has the meaning set forth in
<U>Section&nbsp;4.11(a)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">&#147;<U>Code</U>&#148; means the United States Internal Revenue Code of 1986, as amended.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">&#147;<U>Common Stock</U>&#148; means the common stock, par value $0.001 per share, of QLT USA.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Confidentiality Agreement</U>&#148; means that certain Confidentiality Agreement, dated as of
February&nbsp;20, 2008, between Seller and an Affiliate of Purchaser.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Contract</U>&#148; means any written agreement, contract, understanding, arrangement,
instrument, note, mortgage, indenture, guaranty, option, indemnity, warranty, deed, assignment,
power of attorney, certificate, sale or purchase order, work order, insurance policy, lease,
license or commitment to which a specified Person is a party or by which any of its Assets are
bound.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Copyright</U>&#148; means all registered and unregistered copyrights in both published and
unpublished works, rights in mask works and mask works applications, all sui generis rights in data
and databases, and any other rights of authorship in any other published and unpublished works,
including all moral rights in any of the foregoing.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">&#147;<U>Covered Parties</U>&#148; has the meaning set forth in <U>Section&nbsp;11.2(a)(ii)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">&#147;<U>Damages</U>&#148; has the meaning set forth in <U>Section&nbsp;11.2(a)(i)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">&#147;<U>Deferred Payments</U>&#148; has the meaning set forth in <U>Section&nbsp;9.4(e)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">&#147;<U>Dispute Notice</U>&#148; has the meaning set forth in <U>Section&nbsp;11.3(b)</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Distribution</U>&#148; means any and all activities related to the distribution, marketing,
promoting, offering for sale and selling of any product (whether directly or through other
marketing licensees), including packaging, advertising, detailing, educating, planning, promoting,
performing, reporting, storing, handling, shipping and communicating with Governmental Authorities
and third parties in connection therewith.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">&#147;<U>Effective Time</U>&#148; has the meaning set forth in <U>Section&nbsp;3.1</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Encumbrance</U>&#148; means any security interest, pledge, hypothecation, mortgage, lien,
charge or other encumbrance, other than any licenses of Intellectual Property.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Entity</U>&#148; means any corporation (including any non-profit corporation), general
partnership, limited partnership, limited liability partnership, joint venture, estate, trust,
company (including any company limited by shares, limited liability company or joint stock
company), firm, society or other incorporated or unincorporated enterprise, association,
organization or entity.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">&#147;<U>ERISA</U>&#148; has the meaning set forth in <U>Section&nbsp;4.13(b)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">&#147;<U>ERISA Affiliate</U>&#148; has the meaning set forth in <U>Section&nbsp;4.13(b)</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Escrow Agreement</U>&#148; means the Escrow Agreement by and among Seller, Purchaser and the
Escrow Agent regarding the payment of the Post-Closing Royalty Payments, in a form mutually agreed
upon between the parties, to be executed following the Closing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">[*] Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.
</DIV>

<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Exchange Act</U>&#148; means the United States Securities Exchange Act of 1934, as amended,
and the rules and regulations promulgated thereunder.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">&#147;<U>Excluded Assets</U>&#148; has the meaning set forth in <U>Section&nbsp;2.1(a)(ii)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">&#147;<U>Excluded Liabilities</U>&#148; has the meaning set forth in <U>Section&nbsp;2.1(b)(ii)</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Excluded Liabilities Assignment, Assumption and Release Documents</U>&#148; means documents
reasonably satisfactory to Purchaser evidencing the assignment and assumption of all Excluded
Liabilities and the full and final release of QLT USA therefrom.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">&#147;<U>Execution Date</U>&#148; means the date set forth in the first paragraph of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>FDA</U>&#148; means the United States Food and Drug Administration, or any successor agency
thereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Four Month Product</U>&#148; means the 30.0 mg formulation comprised of leuprolide acetate in
an Atrigel<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> delivery system that provides for the sustained release of leuprolide acetate over a
period of about 120 days and not less than 112 days with a primary indication for the palliative
treatment of prostate cancer.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Future Product</U>&#148; means any Atrigel-based product sold pursuant to the Sanofi Agreement
or MediGene Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">&#147;<U>GAAP</U>&#148; means United States generally accepted accounting principles.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Governmental Authority</U>&#148; means any nation or government, any provincial, state,
regional, local or other political subdivision thereof, any supranational organization of sovereign
states, and any entity, department, commission, bureau, agency, authority, board, court, official
or officer, domestic or foreign, exercising executive, judicial, regulatory or administrative
functions of or pertaining to government.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>HSR Act</U>&#148; means the U.S. Hart-Scott-Rodino Antitrust Improvements Act of 1976, as
amended, and the rules and regulations promulgated thereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>In-License Contract</U>&#148; means any Contract under which QLT USA has been granted any
license, permission or any other right to utilize or otherwise exploit any Intellectual Property.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>In-Licensed IP</U>&#148; means the Intellectual Property that is licensed to QLT USA under or
through an In-License Contract.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">&#147;<U>Included Assets</U>&#148; has the meaning set forth in <U>Section&nbsp;2.1(a)(i)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">&#147;<U>Included Liabilities</U>&#148; has the meaning set forth in <U>Section&nbsp;2.1(b)(i)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">&#147;<U>Indemnified Party</U>&#148; has the meaning set forth in <U>Section&nbsp;11.3(a)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">&#147;<U>Indemnifying Party</U>&#148; has the meaning set forth in <U>Section&nbsp;11.3(a)</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Intellectual Property</U>&#148; means any intellectual property or industrial property that
may exist or be created under the laws of any jurisdiction throughout the world, including all
Trademarks, Copyrights, Know-How and Patents, whether registered or unregistered, and all
applications and registrations therefor (whether pending, existing, abandoned or expired).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#091;*&#093; Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.
</DIV>

<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Intercompany Loan Receivable</U>&#148; means those certain promissory notes aggregating &#091;*&#093;
million in principal amount, plus accrued and unpaid interest thereon, issued by Seller to QLT USA.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">&#147;<U>IRS</U>&#148; means the Internal Revenue Service of the United States.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Know-How</U>&#148; means all information that derives economic value from not being generally
known to other Persons, all information that is proprietary or confidential to a specified Person,
and any trade secrets, confidential information, know-how, and similar or analogous rights in
ideas, inventions, discoveries, models, developments, improvements, procedures, processes,
techniques, devices, methods, patterns, formulations, specifications, documentation, information,
lists, software, data, products, technology, plans, drawings, designs, systems, research and
development, materials, or technology, including all biological, chemical, clinical, manufacturing
and other information or data, other than such which is or becomes the subject of a Patent.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Knowledge</U>&#148; means, with respect to Seller, the actual knowledge of the Persons set
forth on <U>Schedule&nbsp;1.1(b)</U> hereto, and with respect to Purchaser, the actual knowledge of the
Persons set forth on <U>Schedule&nbsp;1.1(c)</U> hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Law</U>&#148; means each provision of any currently existing federal, provincial, state, local
or foreign law, statute, ordinance, order, code, rule or regulation, promulgated or issued by any
Governmental Authority, as well as any judgments, decrees, injunctions or agreements issued or
entered into by any Governmental Authority.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Liability</U>&#148; means, collectively, any indebtedness, guaranty, endorsement, claim, loss,
damage, deficiency, cost, expense, obligation or responsibility, fixed or unfixed, known or
unknown, choate or inchoate, liquidated or unliquidated, secured or unsecured, direct or indirect,
matured or unmatured, or absolute, contingent or otherwise, including any product liability.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Material Adverse Effect</U>&#148; means any occurrence, development, change, event, condition,
circumstance or effect that does or would reasonably be expected to materially and adversely affect
the business, assets, financial condition, liabilities or results of operations of QLT USA or the
Product Line Business, taken as a whole, but, for purposes of this definition, shall exclude:
(a)&nbsp;any occurrence, development, change, event, condition, circumstance or effect that generally
affects the industries in which QLT USA operates or the manufacture and Distribution of the
Product, including changes in Laws, but does not affect QLT USA disproportionately relative to
other participants in the industries in which QLT USA operates in any material respect, (b)&nbsp;general
economic or political conditions, or events, circumstances, changes or effects affecting the
securities markets generally, (c)&nbsp;acts of terrorism or war (whether or not declared) occurring
after the date hereof, (d)&nbsp;changes in GAAP or regulatory accounting requirements, (e)&nbsp;changes
arising from actions, recommendations or decisions of the FDA with respect to new drug
applications, abbreviated new drug applications, supplemental new drug applications or biologics
license applications of QLT USA, which do not affect QLT USA disproportionately, (f)&nbsp;actions by any
of QLT USA&#146;s actual or potential competitors with respect to the Product or the Product Line
Business, (g)&nbsp;the consummation of the Transaction or the announcement of the execution of this
Agreement, or (h)&nbsp;Seller&#146;s compliance with the terms of this Agreement or any Other Transaction
Document.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Material Contract</U>&#148; means each Contract of QLT USA set forth on
<U>Schedule&nbsp;1.1(d)</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Medical Product Regulatory Authority</U>&#148; means any Governmental Authority that is
concerned with the safety, efficacy, reliability, manufacture, investigation, sale or marketing of
pharmaceuticals, medical products, biologics or biopharmaceuticals, including the FDA.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#091;*&#093; Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.
</DIV>

<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">&#147;<U>MediGene</U>&#148; means MediGene Aktiengesellschaft.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>MediGene Agreement</U>&#148; means the Collaboration, License and Supply Agreement, dated as
of April&nbsp;4, 2001, between Atrix Laboratories, Inc. and MediGene, as amended pursuant to (a)&nbsp;the 1.
Amendment of the Collaboration, License and Supply Agreement effective April&nbsp;4, 2001 between Atrix
Laboratories, Inc. and MediGene concerning AE Exchange, (b)&nbsp;the Second Amendment to Collaboration,
License and Supply Agreement between Atrix Laboratories, Inc. and MediGene as of December&nbsp;22, 2003
and (c)&nbsp;the Third Amendment to Collaboration, License and Supply Agreement dated May&nbsp;17, 2006
between QLT USA and MediGene.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">&#147;<U>Noncompete Period</U>&#148; has the meaning set forth in <U>Section&nbsp;7.4(a)</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>One Month Product</U>&#148; mean the 7.5 mg formulation comprised of leuprolide acetate in an
Atrigel<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> delivery system that provides for the sustained release of leuprolide acetate over a
period of about thirty (30) days and not less than twenty-eight (28) days with a primary indication
for the palliative treatment of prostate cancer.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Ordinary Course of Business</U>&#148; means, with respect to any Person, any action taken by
such Person that is consistent in nature, scope and magnitude with the past practices of such
Person and is taken in the ordinary course of the normal, day-to-day operations of such Person.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Other Transaction Documents</U>&#148; means the Excluded Liabilities Assignment, Assumption
and Release Documents, the Escrow Agreement, the Affiliate Resolution Agreement and the Trademark
and Trade Name License Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Out-License Contract</U>&#148; means any Contract under which QLT USA has granted a license to
any Person to utilize or otherwise exploit any Intellectual Property with respect to Products.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Party</U>&#148; or &#147;<U>Parties</U>&#148; has the meaning set forth in the first paragraph of this
Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Patent</U>&#148; means any United States or non-United States patent, patent application,
patent disclosure, invention disclosure or other rights relating to the protection of inventions
worldwide and all rights related thereto, including all original applications, reissues,
reexaminations, divisionals, continuations, continuations-in-part, continuing applications,
re-examinations, extensions, reissues, or renewals of any of the foregoing, and all counterparts
claiming priority therefrom.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Permitted Encumbrances</U>&#148; means (a) (i)&nbsp;statutory liens for current Taxes not yet
delinquent or (ii)&nbsp;Taxes being contested in good faith by appropriate proceedings and which have
been appropriately reserved for on QLT USA&#146;s balance sheet, (b)&nbsp;mechanics&#146;, carriers&#146;, workers&#146;,
repairers&#146; and other similar liens arising by operation of law and incurred in the Ordinary Course
of Business of QLT USA relating to obligations as to which there is no default on the part of QLT
USA or the validity or amount of which is being contested in good faith by appropriate proceedings,
(c)&nbsp;pledges, deposits or other liens securing the performance of bids, trade contracts, leases or
statutory obligations (including workers&#146; compensation, unemployment insurance or other social
security legislation) arising or incurred in the Ordinary Course of Business of QLT USA and (d)&nbsp;any
Contract listed in <U>Section&nbsp;4.6</U> of the Seller Disclosure Schedule that constitutes an
Encumbrance.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">&#147;<U>Person</U>&#148; means any individual, Entity or Governmental Authority.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Post-Closing Royalty Amounts</U>&#148; means the Royalty Amounts for sales occurring during
the quarter ended September&nbsp;30, 2009 and during each quarter following the Effective Time, as
applicable.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#091;*&#093; Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.
</DIV>

<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Product</U>&#148; means, collectively, the One Month Product, Three Month Product, Four Month
Product and Six Month Product.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Product Equipment</U>&#148; means, the tools and manufacturing equipment owned by QLT USA and
used to test the Product as set forth on <U>Schedule&nbsp;1.1(g)</U> hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Product Line Business</U>&#148; means the rights in and related to the Product and the
Distribution of the Product.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Product Records</U>&#148; means to the extent permitted by Law, all books and records relating
to the Product, including copies of all material customer and supplier lists, account lists, call
data, sales history, call notes, marketing studies, consultant reports, physician databases and
correspondence (excluding invoices) with respect to the Product or the Product Line Business to the
extent maintained by or in the possession of QLT USA, Seller or any other Subsidiary of Seller, and
all complaint files and adverse event files with respect to the Product, <I>provided, however, </I>that
(a)&nbsp;Seller may retain: (i)&nbsp;a copy of any such books and records to the extent necessary for Tax,
accounting, litigation or other valid business purposes, (ii)&nbsp;a copy of any such books and records
to the extent such books and records relate to the Product or Product Line Business and (iii)&nbsp;all
books, documents, records and files prepared in connection with or relating to the Transaction,
including bids received from other parties and strategic, financial or Tax analyses relating to the
Included Assets or Included Liabilities, (b)&nbsp;any attorney work product, attorney-client
communications and other items protected by privilege shall be excluded, and (c)&nbsp;Seller shall be
entitled to redact from any such books and records any information that does not relate to the
Included Assets or Included Liabilities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Product Trade Dress</U>&#148; means the trade dress, package designs, product inserts, labels,
logos and associated artwork held by QLT USA used in connection with the Product or the packaging
therefor in the Territory in the form set forth on <U>Schedule&nbsp;1.1(j)</U> hereto, but specifically
excluding all QLT USA Brands used thereon.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Promotional Materials</U>&#148; means the advertising, promotional and media materials, sales
training materials (including any related outlines and quizzes/answers, if any), trade show
materials (including displays) and videos to the extent owned by and in the possession of QLT USA,
Seller or any other Subsidiary of Seller, including materials containing post-marketing clinical
data, if any, used for the Distribution of the Product in all or any part of the Territory
(including Distribution and sales promotion information, market research studies and toll-free
telephone numbers) and relating to the Included Assets, including those materials set forth on
<U>Schedule&nbsp;1.1(k)</U> hereto.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">&#147;<U>PTO</U>&#148; means the United States Patent and Trademark Office.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">&#147;<U>Purchase Price</U>&#148; has the meaning set forth in <U>Section&nbsp;2.2(b)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">&#147;<U>Purchaser</U>&#148; has the meaning set forth in the first paragraph of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Purchaser Competitive Activity</U>&#148; means the distribution, marketing, licensing or sale
of any Purchaser Competitive Product in the &#147;Territory&#148; (as defined in each of the Sanofi Agreement
and MediGene Agreement, as applicable).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Purchaser Competitive Product</U>&#148; means &#091;*&#093;.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#091;*&#093; Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.
</DIV>

<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Purchaser Indemnified Parties</U>&#148; has the meaning set forth in <U>Section
11.2(a)(i)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">&#147;<U>QLT USA</U>&#148; has the meaning set forth in the introduction of this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">&#147;<U>QLT USA Benefit Plan</U>&#148; has the meaning set forth in <U>Section&nbsp;4.13(b)</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>QLT USA Brands</U>&#148; means the Trademarks, housemarks, tradenames, and trade dress owned
or used by QLT USA, whether or not registered, other than the QLT USA Marks.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>QLT USA Copyrights</U>&#148; means those Copyrights set forth on <U>Schedule&nbsp;1.1(e)</U>
hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>QLT USA Domain Names</U>&#148; means those domain names set forth on <U>Schedule&nbsp;1.1(f)</U>
hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>QLT USA Intellectual Property</U>&#148; means the QLT USA Patent Rights, QLT USA Copyrights,
QLT USA Domain Names, QLT USA Know-How, QLT USA Marks and Product Trade Dress.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">&#147;<U>QLT USA Know-How</U>&#148; means the Know-How owned by or licensed to QLT USA.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>QLT USA Mark(s)</U>&#148; means those Trademark(s), applications and registrations therefor,
and all common law rights set forth on <U>Schedule&nbsp;1.1(h)</U> hereto, which include the Trademark
&#147;Eligard&#148; and/or any other Trademark registered with the PTO or other equivalent Governmental
Authority which is utilized by QLT USA in the Territory to identify the Product in the Territory,
and all common law rights, applications and registrations therefor, and all goodwill associated
therewith.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>QLT USA Patent Rights</U>&#148; means those Patents set forth on <U>Schedule&nbsp;1.1(i)</U>
hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Registrations</U>&#148; means the regulatory approvals, authorizations, licenses,
applications, agreements, permits and other permissions held by QLT USA and issued by any
Governmental Authority in all or any part of the Territory as set forth on <U>Schedule&nbsp;1.1(l)</U>
hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Representatives</U>&#148; means, with respect to any Person, the directors, officers,
managers, employees, independent contractors, agents or consultants of such Person.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Royalty Amounts</U>&#148; means all royalties received by QLT USA, or any successor or
permitted assignee thereof, pursuant to the Sanofi Agreement and the MediGene Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">&#147;<U>Sanofi</U>&#148; means Sanofi-Synthelabo Inc.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Sanofi Agreement</U>&#148; means the Collaboration, License and Supply Agreement, dated as of
December&nbsp;8, 2000, between Atrix Laboratories, Inc. and Sanofi, as amended pursuant to (a)&nbsp;the First
Amendment to Collaboration, License and Supply Agreement between Atrix Laboratories, Inc. and
Sanofi as of December&nbsp;21, 2001, (b)&nbsp;the Second Amendment to Collaboration, License and Supply
Agreement between Atrix Laboratories, Inc. and Sanofi as of March&nbsp;7, 2002, (c)&nbsp;the letter agreement
between Atrix Laboratories, Inc. and Sanofi dated August&nbsp;22, 2003, (d)&nbsp;the Fourth Amendment to
Collaboration, License and Supply Agreement between QLT USA and Sanofi as of March&nbsp;1, 2005, (e)&nbsp;the
letter agreement between Sanofi and QLT USA dated November&nbsp;14, 2007 and (f)&nbsp;the Sixth Amendment to
Collaboration, License and Supply Agreement between QLT USA and Sanofi as of July&nbsp;1, 2009.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">&#147;<U>SEC</U>&#148; means the United States Securities and Exchange Commission.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Securities Act</U>&#148; means the United States Securities Act of 1933, as amended, and the
rules and regulations promulgated thereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#091;*&#093; Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.
</DIV>

<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">&#147;<U>Seller</U>&#148; has the meaning set forth in the first paragraph of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Seller Competitive Activity</U>&#148; means the distribution, marketing, licensing or sale of
any Seller Competitive Product in the Territory.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Seller Competitive Product</U>&#148; means &#091;*&#093;.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Seller Deposit Account</U>&#148; means one or more deposit accounts to be designated by Seller
in a written notice to Purchaser at least two Business Days prior to the date the applicable
payment is to be made; provided that, if, following the Closing Date, no new deposit account(s)
is/are designated by Seller, Purchaser shall deposit the applicable payment in the deposit
account(s) last designated by Seller.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Seller Disclosure Schedule</U>&#148; means the disclosure schedules delivered by Seller to
Purchaser regarding QLT USA in connection with this Agreement (it being expressly agreed that
disclosure of any item or matter under any Section or subsection in such Seller Disclosure
Schedule, or in attachments thereto, and documents referred to therein, shall be deemed disclosure
for all purposes of <U>ARTICLE IV</U> to the extent such disclosure is reasonably apparent).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">&#147;<U>Seller Indemnified Parties</U>&#148; has the meaning set forth in <U>Section&nbsp;11.2(a)(ii)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">&#147;<U>Shares</U>&#148; means the issued and outstanding shares of Common Stock of QLT USA.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Six Month Product</U>&#148; means the 45.0 mg formulation comprised of leuprolide acetate in
an Atrigel<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> delivery system that provides for the sustained release of leuprolide acetate over a
period of about 180 days and not less than 168 days with a primary indication for the palliative
treatment of prostate cancer.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Subsidiary</U>&#148; means, with respect to any specified Person, any and all Entities
controlled by such specified Person. For purposes of this definition, (a) &#147;control&#148; when used with
respect to any Entity means the power to direct the management and policies of such Entity,
directly or indirectly, whether through ownership of voting securities, by contract or otherwise
and (b)&nbsp;a specified Person shall be deemed, in any event, to control any Entity if such specified
Person is the beneficial owner (as defined in Rule&nbsp;13d-3 of the Exchange Act) of more than 50% of
the voting securities, voting ownership interests or voting partnership interests of such Entity.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">&#147;<U>Survival Period</U>&#148; has the meaning set forth in <U>Section&nbsp;11.1</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Tax</U>&#148; or &#147;<U>Taxes</U>&#148; means any and all taxes, assessments, levies, tariffs, duties
or other charges or impositions in the nature of a tax (together with any and all interest,
penalties, additions to tax and additional amounts imposed with respect thereto) imposed by any
Taxing Authority, including income, estimated income, gross receipts, profits, business, license,
occupation, franchise, capital stock, real or personal property, sales, use, transfer, value added,
employment or unemployment, social security, disability, alternative or add-on minimum, customs,
excise, stamp, environmental, commercial rent or withholding taxes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#091;*&#093; Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.
</DIV>

<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Tax Return</U>&#148; means any report, return (including any information return), claim for
refund, election, estimated Tax filing or payment, request for extension, document, declaration or
other information or filing required to be supplied to any Taxing Authority, including attachments
thereto and amendments thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Taxing Authority</U>&#148; means the IRS and any other domestic or foreign Governmental
Authority responsible for the administration or collection of any Taxes.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">&#147;<U>Territory</U>&#148; means the entire world.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Third Party Acquisition</U>&#148; means (a)&nbsp;the acquisition by a Person, other than Purchaser
and its Affiliates, of any interest in the Included Assets, whether by purchase, issuance or sale
or other disposition of capital stock of QLT USA, sale, lease, license or other disposition of
Assets of QLT USA, by merger or consolidation or otherwise, other than an acquisition of any
capital stock of Seller pursuant to a merger, tender offer or otherwise, or (b)&nbsp;any other
transaction that would prevent, interfere with or delay the Transaction.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Three Month Product</U>&#148; means the 22.5 mg formulation comprised of leuprolide acetate in
an Atrigel<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> delivery system that provides for the sustained release of leuprolide acetate over a
period of about 90 days and not less than 84 days with a primary indication for the palliative
treatment of prostate cancer.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Trademark</U>&#148; means all trademarks, service marks, certification marks, Internet domain
names (other than QLT USA Domain Names), trade names, housemarks, identifying symbols, designs,
product names, business and company names, slogans, logos or insignia, whether registered or
unregistered, all common law rights, applications and registrations therefor, and all goodwill
associated therewith.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Trademark and Trade Name License Agreement</U>&#148; means the Trademark and Trade Name
License Agreement by and between Seller and QLT USA, dated of even
date herewith.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">&#147;<U>Transaction</U>&#148; means the share purchase transaction contemplated by this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<U>Transfer Taxes</U>&#148; means any and all transfer, documentary, sales, use, gross receipts,
stamp, registration, value added, recording, escrow and other similar Taxes and fees (including any
penalties and interest) incurred in connection with the Transaction (including recording and escrow
fees and any real property or leasehold interest transfer or gains Tax and any similar Tax).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<u>United States</u>&#148; means the United States of America.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">&#147;<u>WARN</u>&#148; means the Worker Adjustment and Retraining Notification Act.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">1.2 Other Definitional Provisions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(a)&nbsp;When a reference is made in this Agreement to an Article, Section, Exhibit or Schedule,
such reference is to an Article or Section of, or an Exhibit or Schedule to, this Agreement unless
otherwise indicated.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(b)&nbsp;The words &#147;hereof,&#148; &#147;herein,&#148; &#147;hereto&#148; and &#147;hereunder&#148; and words of similar import, when
used in this Agreement, shall refer to this Agreement as a whole and not to any particular
provision of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#091;*&#093; Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.
</DIV>

<P align="center" style="font-size: 10pt; text-indent: 8%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(c)&nbsp;The terms defined in the singular have a comparable meaning when used in the plural, and
vice versa.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(d)&nbsp;Whenever the context requires, words of one gender include the other gender and the neuter
form.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(e)&nbsp;References to a Person are also to its successors and permitted assigns.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(f)&nbsp;The word &#147;or&#148; is not exclusive.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(g)&nbsp;Unless the context requires otherwise, any definition of or reference to any Contract
herein shall be construed as referring to such Contract as from time to time amended, supplemented
or otherwise modified (subject to any restrictions on such amendments, supplements or modifications
set forth therein or herein).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(h)&nbsp;The term &#147;dollars&#148; and &#147;$&#148; means United States dollars.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(i)&nbsp;The word &#147;including&#148; means &#147;including without limitation&#148; and the words &#147;include&#148; and
&#147;includes&#148; have corresponding meanings.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>ARTICLE II<BR>
ASSETS AND LIABILITIES OF QLT USA; PURCHASE AND SALE OF SHARES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">2.1 <U>Assets and Liabilities of QLT USA</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(a)&nbsp;<U>Assets</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 12%">(i)&nbsp;<U>Included Assets</U>. The Parties acknowledge and agree that, as of the Closing, QLT
USA will hold the rights to those Assets set forth on <U>Schedule&nbsp;2.1(a)(i)</U> (the &#147;<U>Included
Assets</U>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 12%">(ii)&nbsp;<U>Excluded Assets</U>. The Parties acknowledge and agree that, as of the Closing, QLT
USA will not hold any rights whatsoever to those Assets set forth on <U>Schedule&nbsp;2.1(a)(ii)</U>,
and, by purchasing the Shares, Purchaser is not acquiring any rights whatsoever to the Assets set
forth on <U>Schedule&nbsp;2.1(a)(ii)</U> (the &#147;<U>Excluded Assets</U>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(b)&nbsp;<U>Liabilities</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 12%">(i)&nbsp;<U>Included Liabilities</U>. The Parties acknowledge and agree that, as of the Closing,
QLT USA will be responsible for all Liabilities related to the Included Assets (the &#147;<U>Included
Liabilities</U>&#148;), other than the Excluded Liabilities. For the avoidance of doubt, all
Liabilities for Taxes of QLT USA as of the Closing, including without limitation all such
Liabilities arising from or relating to any intercompany relationship or intercompany transaction
involving QLT USA, shall be Included Liabilities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 12%">(ii)&nbsp;<U>Excluded Liabilities</U>. The Parties acknowledge and agree that, as of the Closing,
QLT USA will not (except as otherwise provided herein) be responsible for any Liabilities related
to the Excluded Assets or any of the Liabilities set forth on <U>Schedule&nbsp;2.1(b)(ii)</U> (the
&#147;<U>Excluded Liabilities</U>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#091;*&#093; Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.
</DIV>

<P align="center" style="font-size: 10pt; text-indent: 12%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">2.2 <U>Purchase and Sale of Shares; Purchase Price</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(a)&nbsp;At the Closing, upon the terms and subject to the conditions contained in this Agreement,
Seller shall sell to Purchaser, and Purchaser shall purchase from Seller, the Shares free and clear
of all Encumbrances.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(b)&nbsp;The aggregate purchase price in full payment for the Shares shall be the sum of the
following amounts (the &#147;<U>Purchase Price</U>&#148;) and shall be paid or delivered as follows:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>(A) $20.0&nbsp;million to Seller Deposit Account at
the Closing,</TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>(B) <U>plus</U> a cash amount equal to the amount of cash set forth
on the Closing Date Balance Sheet and held by QLT USA as of the
Closing Date, to Seller Deposit Account after the Closing, on the
first Business Day following the Closing Date,</TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>(C) <U>plus</U> a cash amount equal to the amount of Cash
Equivalents held by QLT USA as of immediately prior to the Closing
Date and converted from Cash Equivalents to cash, to Seller Deposit
Account after the Closing, on the first Business Day following the
Closing Date and</TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>(D) <U>plus</U> a cash amount equal to the principal amount
outstanding of, and the amount of accrued and unpaid interest on, the
Intercompany Loan Receivable held by QLT USA as of the Closing Date
after the Closing, on the first Business Day following the Closing
Date,</TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>$10.0&nbsp;million to Seller Deposit Account no
later than the first anniversary of the Closing Date, and</TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(iii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>An aggregate of $200.0&nbsp;million (excluding the
payments described under <U>Sections&nbsp;2.2(b)(i)</U> and <U>(ii)</U>)
to Seller Deposit Account, in quarterly installments, for the quarter
ended September&nbsp;30, 2009 and for each full quarter thereafter, payable
no later than fifty (50)&nbsp;days following the last date of each such
quarter, with each such installment to be in an amount that is equal to
80% of the Post-Closing Royalty Amounts paid to QLT USA and/or any
successor or permitted assignee thereof for such quarter, calculated in
accordance with the terms of each of the Sanofi Agreement and MediGene
Agreement in effect as of the Closing Date.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(c)&nbsp;Notwithstanding the payment terms set forth in <U>Section&nbsp;2.2(b)(iii)</U> above, upon at
least two (2)&nbsp;Business Days written notice to Seller, at any time or from time to time, Purchaser
or an Affiliate thereof may prepay to Seller, in whole or in part, without premium or penalty, the
balance of the $200.0&nbsp;million not previously paid to Seller pursuant to <U>Section&nbsp;2.2(b)(iii)</U>
by depositing the amount to be prepaid into the Seller Deposit Account. For the avoidance of
doubt, in the event the amount prepaid is less than the unpaid portion of the $200.0&nbsp;million set
forth in <U>Section&nbsp;2.2(b)(iii)</U>, the quarterly payment obligations set forth in <U>Section
2.2(b)(iii)</U> above with respect to such unpaid portion shall continue as set forth therein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#091;*&#093; Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->12<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>ARTICLE III<BR>
CLOSING</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">3.1 <U>Closing</U>. Upon the terms and subject to the conditions of this Agreement, the
Closing shall be held on the Execution Date, such date (the &#147;<U>Closing Date</U>&#148;) being after
satisfaction or waiver of all of the conditions set forth in <U>ARTICLE VIII</U> at the offices of
Latham &#038; Watkins LLP, 140 Scott Drive, Menlo Park, California 94025, unless the Parties otherwise
agree. The Parties will exchange (or cause to be exchanged) at the Closing the funds, agreements,
instruments, certificates and other documents, and do, or cause to be done, all of the things
respectively required of each Party as specified in <U>Section&nbsp;3.2</U>. The Closing shall be
deemed to have occurred upon receipt by Seller of the cash payment set forth in Section
2.2(b)(i)(A) on the Closing Date (the &#147;<U>Effective Time</U>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">3.2 <U>Deliveries on the Closing Date and after the Closing</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(a)&nbsp;At the Closing, Seller will deliver or cause to be delivered to Purchaser:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the stock certificate representing the Shares,
duly endorsed in blank or accompanied by duly executed assignment
documents,</TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>an IRS Form W-8BEN, with parts I and II thereof
completed by Seller as reasonably requested by Purchaser to establish
that the payments by Purchaser to Seller pursuant to <U>Section
2.2(b)</U> are exempt from withholding, and duly executed by Seller,</TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(iii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>written resignations of all officers and
directors of QLT USA,</TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(iv)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Excluded Liabilities Assignment, Assumption
and Release Documents, duly executed by all the parties thereto,</TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(v)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>all of the Financial Statements and supporting
schedules described in <U>Section&nbsp;4.11(a)</U>,</TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(vi)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>a true, correct and complete list of each
material filing and payment that, to Seller&#146;s Knowledge and to the
knowledge of Seller&#146;s outside intellectual property counsel, must be
made on or before the date that is ninety (90)&nbsp;days after the Closing
Date with respect to the Intellectual Property set forth on
<U>Schedules 1.1(e), (f), (h)&nbsp;and (i)</U>;</TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(vii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>revocations of any and all powers of attorney
heretofore granted by QLT USA or Seller or any of its Affiliates that,
prior to the Closing Date, Purchaser and Seller have mutually agreed
are to be revoked,</TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(viii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the certificate of incorporation of QLT USA, certified by the
Delaware Secretary of State on or promptly before the Closing Date, and
a certificate of good standing of QLT USA issued by the Delaware
Secretary of State on or promptly before the Closing Date, and</TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(ix)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>a certified copy of the Certificate of
Amalgamation and Notice of Articles of Seller in effect as of the
Closing Date.
</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#091;*&#093; Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->13<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">
<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 8%">(b)&nbsp;At the Closing, Purchaser will deliver or cause to be delivered to Seller:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>by wire transfer to the Seller Deposit Account,
immediately available dollar funds in an amount equal to the portion of
the Purchase Price set forth in <U>Section&nbsp;2.2(b)(i)(A)</U>, and</TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the certificate of incorporation of Purchaser,
certified by the Delaware Secretary of State on or promptly before the
Closing Date, and a certificate of good standing of Purchase, issued by
the Delaware Secretary of State on or promptly before the Closing Date.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(c)&nbsp;After the Closing, on the first Business Date following the Closing Date, (i)&nbsp;Purchaser
will deliver or cause to be delivered to Seller, by wire transfer to the Seller Deposit Account,
immediately available dollar funds in an amount equal to the portion of the Purchase Price set
forth in <U>Sections&nbsp;2.2(b)(i)(B)</U>, <U>2.2(b)(i)(C)</U> and <U>2.2(b)(i)(D)</U> and (ii)
Seller will deliver or cause to be delivered to Purchaser, by wire transfer to an account
designated by Purchaser prior to the Closing, immediately available dollar funds in an amount equal
to the amount due under the Intercompany Loan Receivable as of the Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">3.3 <U>Post-Closing Deliveries</U>. As soon as reasonably practicable following the Closing
Date, but in any event within thirty (30)&nbsp;days thereafter with respect to (i), (iii), (iv), (v)&nbsp;and
(vi)&nbsp;and within sixty (60)&nbsp;days thereafter with respect to (ii), Seller shall deliver or cause to
be delivered to Purchaser or QLT USA, as requested by Purchaser, the following deliverables:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>all books and records of QLT USA, including all
minute books (containing records of meetings of stockholders, the board
of directors and any committee thereof), the stock certificate books,
the stock record books for QLT USA, all Promotional Materials and all
Contracts to which it is a party and by which it or the Included Assets
are bound,</TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>all financial documents and records of QLT USA,</TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(iii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>all Product Records, all regulatory filings
and all correspondence from any and all Governmental Authorities, in
each case relating to any Product, the Product Line Business or other
Included Asset,</TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(iv)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>all stability samples and related testing and
other records, in each case relating to any Product, the Product Line
Business or other Included Asset,</TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(v)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>all batch records relating to any Product, the
Product Line Business or other Included Asset, and</TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(vi)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>all testing and other records related to any Product or the Product
Line Business.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#091;*&#093; Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>ARTICLE IV<BR>
REPRESENTATIONS AND WARRANTIES REGARDING QLT USA</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Except as otherwise set forth on the Seller Disclosure Schedule, Seller hereby represents and
warrants to Purchaser as of the Execution Date as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">4.1 <U>Organization; Corporate Records</U>. QLT USA is a corporation duly organized, validly
existing and in good standing under the laws of Delaware. QLT USA has all requisite corporate
power and authority and all licenses, permits and authorizations necessary to carry on the business
in which it is engaged and to own and use the Assets owned and used by it. QLT USA is duly
qualified to do business as a foreign corporation and is in good standing in every jurisdiction
where such qualification is required, except where the failure to be so qualified or in good
standing would not constitute a Material Adverse Effect. Section&nbsp;4.1 of the Seller Disclosure
Schedule contains a true, correct and complete list of all directors and officers of QLT USA. At
the Closing, Seller has delivered to Purchaser true, correct and complete copies of the Certificate
of Incorporation and the Bylaws. The minute books (containing records of meetings of stockholders,
the board of directors and any committee thereof), the stock certificate books and the stock record
books for QLT USA are correct and complete in all material respects. QLT USA is not in default
under or in violation of any provision of its Certificate of Incorporation or Bylaws.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">4.2 <U>No Conflicts</U>. The execution, delivery and performance of this Agreement and the
Other Transaction Documents and the consummation of the transactions contemplated hereby and
thereby:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(a)&nbsp;are not prohibited or limited by, do not and will not violate or contravene, do not and
will not conflict with, and do not and will not result in the breach of or a default under, any
provision of the Certificate of Incorporation or Bylaws,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(b)&nbsp;assuming all of the consents, approvals, authorizations and permits necessary for the
consummation of the Transaction have been obtained and all the filings and notifications necessary
for the consummation of the Transaction have been made and any waiting periods thereunder have
terminated or expired, do not and will not conflict with any Law to which QLT USA is subject or by
which QLT USA is bound or to which any of the Included Assets is subject, or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(c)&nbsp;except as does not, or would not reasonably be expected to, result in, individually or in
the aggregate, a Material Adverse Effect, do not and will not violate or contravene, conflict with,
result in a breach of, constitute (with or without due notice or lapse of time or both) a default
under, result in the acceleration of obligations under, create in any party the right to terminate,
modify or cancel, or require any notice, consent or waiver under, (i)&nbsp;any Material Contract or (ii)
any award, judgment, rule, charge, order, writ, injunction or decree of any Governmental Authority
to which QLT USA is a party or by which any of the Included Assets is subject.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">4.3 <U>Capitalization</U>. The authorized capital stock of QLT USA consists of 1,000 shares
of Common Stock, of which 100 shares are issued and outstanding. There are no shares of Common
Stock or other capital stock or equity securities of QLT USA issued, reserved for issuance or
outstanding and no outstanding or authorized options, warrants, convertible or exchangeable
securities, subscriptions, rights (including any purchase, subscription, conversion, exchange or
preemptive rights), stock appreciation rights, phantom stock, profit participation or similar
rights, calls or commitment of any character whatsoever to which QLT USA is a party or subject or
by which QLT USA is bound requiring the issuance or sale of shares of any capital stock of QLT USA.
There are no voting trusts, proxies, or other agreements or understandings with respect to the
voting of the capital stock of QLT USA. All of the Shares have been duly authorized and validly
issued, are fully paid and nonassessable and are free of any preemptive rights with respect
thereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#091;*&#093; Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->15<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">4.4 <U>Title</U>. QLT USA has good and marketable title to, a valid leasehold interest in,
or a valid license or other right to use, the Included Assets, free and clear of all Encumbrances,
other than the Permitted Encumbrances.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">4.5 <U>No Subsidiaries</U>. QLT USA has no Subsidiaries. QLT USA does not own or control or
have any right to acquire, directly or indirectly, any capital stock of, or other equity interest
in, any Person.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">4.6 <U>Intellectual Property</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(a)&nbsp;Included in each of Schedules 1.1(e) (QLT USA Copyrights), 1.1(f) (QLT USA Domain Names),
1.1(h) (QLT USA Mark(s)), 1.1(i) (QLT USA Patent Rights) and 1.1(j) (Product Trade Dress) is (i)
the name of the owner of the Intellectual Property covered by such Schedule and (ii)&nbsp;the
jurisdiction(s) by or in which the Intellectual Property covered by such Schedule has been issued
or registered or in which an application for such issuance or registration has been filed,
including the respective registration or application numbers and dates of issuance, registration or
filing. Each of Schedules 1.1(e), 1.1(f), 1.1(h), 1.1(i) and 1.1(j) is a true, correct and
complete list, in all material respects, of all Copyrights, domain names, Trademarks, Patents and
trade dress, respectively, owned or held by QLT USA.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(b)&nbsp;Except as would not, individually or in the aggregate, reasonably be expected to have a
Material Adverse Effect, none of the QLT USA Intellectual Property is the subject of (A)&nbsp;any
pending adverse judgment, injunction, order, decree or agreement restricting (i)&nbsp;its use in
connection with the Product or Product Line Business within the Territory, (ii)&nbsp;assignment of such
QLT USA Intellectual Property by QLT USA or (iii)&nbsp;license of such QLT USA Intellectual Property by
QLT USA or (B)&nbsp;any pending litigation to which QLT USA is a party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(c)&nbsp;To Seller&#146;s Knowledge, there has been (A)&nbsp;no threat or claim of infringement or
misappropriation of third party Intellectual Property made in writing to QLT USA or to Seller or
any of its Subsidiaries relating to QLT USA; and (B)&nbsp;no pending litigation alleging infringement or
misappropriation by QLT USA of third party Intellectual Property to which QLT USA is a party, in
each of case (A)&nbsp;or (B), arising from (i)&nbsp;the practice of the QLT USA Intellectual Property in
connection with the Product Line Business, (ii)&nbsp;the Distribution of the Product or (iii)&nbsp;the
conduct of the business of QLT USA.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(d)&nbsp;Except as would not, individually or in the aggregate, reasonably be expected to have a
Material Adverse Effect, all QLT USA Intellectual Property used in connection with the Product or
Product Line Business within the Territory is owned by or licensed to QLT USA, free and clear of
all Encumbrances (other than Permitted Encumbrances).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(e)&nbsp;Except as would not, individually or in the aggregate, reasonably be expected to have a
Material Adverse Effect, Seller has no Knowledge of any misappropriation or infringement of any of
the QLT USA Intellectual Property used in connection with the Product or Product Line Business by
any Person within the Territory. Seller has made available to Purchaser accurate and complete
copies of all In-License Contracts, all of which are set forth on Section&nbsp;4.6(e) of the Seller
Disclosure Schedule. Each In-License Contract is legal, valid and binding, is in full force and
effect and is enforceable in accordance with its terms with respect to QLT USA and, to the
Knowledge of Seller, each other party thereto.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#091;*&#093; Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.
</DIV>


<P align="center" style="font-size: 10pt; text-indent: 8%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->16<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(f)&nbsp;Seller has made available to Purchaser accurate and complete copies of all Out-License
Contracts, all of which are set forth on Section&nbsp;4.6(f) of the Seller Disclosure Schedule. Each
Out-License Contract is legal, valid and binding, is in full force and effect and is enforceable in
accordance with its terms with respect to QLT USA and, to the Knowledge of Seller, each other party
thereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(g)&nbsp;Except for the In-Licensed IP subject to the In-License Contracts set forth on Section
4.6(e) of the Seller Disclosure Schedule, QLT USA is the sole and exclusive owner of all right,
title and interest in and to all QLT USA Intellectual Property used in connection with the Product
or Product Line Business free and clear of all Encumbrances (other than Permitted Encumbrances).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(h)&nbsp;QLT USA has not initiated any claim against any Person alleging that such Person
infringes, misappropriates or otherwise violates any QLT USA Intellectual Property in any material
respect. To the Knowledge of Seller, no Person has infringed or otherwise misappropriated or is
now infringing or misappropriating any QLT USA Intellectual Property. Since the Atrix Acquisition
Date, QLT USA has not received any written communications alleging that any QLT USA Intellectual
Property is invalid or unenforceable. To Seller&#146;s Knowledge, there has been no prior use of any
Product Marks by any Person that would confer upon such Person superior rights in such Product
Marks. Seller has taken reasonable steps to preserve and maintain records relating to the QLT USA
Intellectual Property since the Atrix Acquisition Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(i)&nbsp;No interference, opposition, reissue, reexamination or other proceeding of any nature is
pending or, to Seller&#146;s Knowledge, threatened in writing, in which the scope, validity or
enforceability of any QLT USA Intellectual Property is being contested or challenged.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(j)&nbsp;All current and former employees, consultants and contractors of QLT USA, and any other
Person involved in the creation or development of any QLT USA Intellectual Property, in each case,
since the Atrix Acquisition Date, have executed a valid and enforceable QLT USA non-disclosure and
invention assignment agreement and a copy of each such agreement has been made available to
Purchaser.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(k)&nbsp;To Seller&#146;s Knowledge, no funding, facilities or personnel of any Governmental Authority
or educational institution were used, directly or indirectly, in any material respect, to develop
or create, in whole or in part, any QLT USA Intellectual Property.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(l)&nbsp;Since the Atrix Acquisition Date, QLT USA has exercised reasonable diligence with respect
to the filing, prosecution, and maintenance of all QLT USA Intellectual Property used in connection
with the Product or Product Line Business. For each issued Patent within the QLT USA Intellectual
Property used in connection with the Product or Product Line Business for which prosecution has
taken place since the Atrix Acquisition Date, to Seller&#146;s Knowledge: (i)&nbsp;all inventors have been
properly identified and named, and (ii)&nbsp;all inventors have executed an assignment of rights to
Seller or its predecessor in interest to such Patent.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">4.7 <U>Litigation</U>. There is no (a)&nbsp;outstanding award, judgment, ruling, charge, order,
writ, injunction or decree of any Governmental Authority or arbitrator to which QLT USA is a party
or by which QLT USA is bound and to which any of the Included Assets is subject, or (b)&nbsp;Action
pending to which QLT USA is party, or (c)&nbsp;to the Knowledge of Seller, Action threatened, by or
against QLT USA, that individually or in the aggregate, does, or would reasonably be expected to,
result in, individually or in the aggregate, a Material Adverse Effect. As of the Execution Date,
to Seller&#146;s Knowledge, there is currently no fact, situation, circumstance, status, condition,
activity, practice, plan, occurrence, event, incident, action, failure to act, or transaction that
would reasonably be expected to form the basis for any such Action.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#091;*&#093; Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.
</DIV>

<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->17<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">4.8 <U>Taxes</U>. Since the Atrix Acquisition Date:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(a)&nbsp;QLT USA has filed when due (taking into account properly obtained extensions) all Tax
Returns that it was required to file under applicable laws and regulations. All such Tax Returns
were accurate, correct and complete in all respects; provided, that no such representation is made
with respect to net operating loss carryforwards, tax credits and similar tax attributes, whether
or not reflected on such Tax Returns, to the extent they relate to periods prior to the Atrix
Acquisition Date. All Taxes shown as payable on any Tax Return have been paid. QLT USA is not
currently the beneficiary of any extension of time within which to file any Tax Return (other than
extensions obtained as a matter of right). QLT USA has not received written notice of any claim by
a Taxing Authority in a jurisdiction where QLT USA does not file Tax Returns that it is or may be
subject to taxation by that jurisdiction. There are no Liens for Taxes (other than Permitted
Encumbrances) upon any of the assets of QLT USA.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(b)&nbsp;QLT USA has withheld and paid all Taxes required to have been withheld and paid in
connection with any amounts paid or owing to any employee, independent contractor, creditor,
stockholder or other third party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(c)&nbsp;No foreign, federal, state, or local Tax audits or administrative or judicial Tax
proceedings are pending with respect to QLT USA (based on notice thereof having been received by
QLT USA) nor, to the Knowledge of Seller, are any foreign, federal, state, or local Tax audits or
administrative or judicial Tax proceedings being conducted with respect to QLT USA. QLT USA has
not received from any foreign, federal, state, or local Taxing Authority (including jurisdictions
where QLT USA has not filed Tax Returns) any (i)&nbsp;written notice indicating an intent to open an
audit or other review with respect to any Tax matter, (ii)&nbsp;request for information related to any
Tax matter, or (iii)&nbsp;written notice of deficiency or proposed adjustment for any amount of Tax
proposed, asserted, or assessed by any Taxing Authority against QLT USA which matter has not been
settled or resolved.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(d)&nbsp;Seller has made available to Purchaser copies of all federal, state, local and foreign
income Tax Returns, and all other material Tax Returns, filed with respect to QLT USA since the
Atrix Acquisition Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(e)&nbsp;QLT USA has not waived any statute of limitations in respect of Taxes or agreed to any
extension of time with respect to a Tax assessment or deficiency. There are no outstanding rulings
of, or requests for rulings by, any Tax Authority that are addressed to QLT USA and that are, or if
issued would be, binding upon QLT USA.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">4.9 <U>Compliance with Laws; Regulatory Matters</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(a)&nbsp;QLT USA has complied with all applicable Laws and each award, judgment, ruling, charge,
order, writ, injunction or decree of any Governmental Authority or arbitrator to which QLT USA is a
party or subject or by which QLT USA is bound and to which any of the Included Assets is subject,
except for any non-compliance that does not, or would not reasonably be expected to, result in,
individually or in the aggregate, a Material Adverse Effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(b)&nbsp;All of the Registrations required for the Distribution of the Product in all or any part
of the Territory in the manner and in the country(ies) in which such activities are currently
conducted are solely and exclusively owned by QLT USA or, to Seller&#146;s Knowledge, QLT USA&#146;s
licensees. Section&nbsp;4.9 of the Seller Disclosure Schedule sets forth a true, correct and complete
list of such Registrations. The Registrations set forth in Section&nbsp;4.9 of the Seller Disclosure
Schedule that are solely and exclusively owned by QLT USA are in full force and effect.
<U>Schedule&nbsp;1.1(a)</U> hereto (Applicable Permits) sets forth a true, correct and complete list of
all material permits, approvals, licenses, franchises or authorizations, other than the
Registrations, from any Governmental Authority held by QLT USA.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#091;*&#093; Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.
</DIV>

<P align="center" style="font-size: 10pt; text-indent: 8%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->18<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(c)&nbsp;To Seller&#146;s Knowledge, the manufacture by third party manufacturers and Distribution by
third parties of the Product in all or any part of the Territory has been conducted in compliance
with the Registrations and all applicable Laws, including the Act, except for any non-compliance
that does not, or would not reasonably be expected to, result in, individually or in the aggregate,
a Material Adverse Effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(d)&nbsp;Since January&nbsp;1, 2007, QLT USA has not received any written or, to Seller&#146;s Knowledge,
other notice of proceedings from a Governmental Authority alleging that the Product or any of the
Included Assets, or the ownership, Distribution thereof, violates any applicable Law in any manner
that has not been remedied, except for such violations that do not, or would not reasonably be
expected to, result in, individually or in the aggregate, a Material Adverse Effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(e)&nbsp;QLT USA has completed and filed all annual and other reports required to be filed by QLT
USA with the FDA, except where failure to file any such report does not, or would not reasonably be
expected to, result in, individually or in the aggregate, a Material Adverse Effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(f)&nbsp;Since January&nbsp;1, 2007, no Product has been voluntarily recalled, suspended or discontinued
by QLT USA at the request of the FDA or any other Governmental Authority, nor has QLT USA received
any notice from the FDA or any other Governmental Authority that it is not in compliance with
applicable requirements under the Act and the regulations promulgated thereunder or similar Laws in
any foreign jurisdiction, including verbal notice or notice in the form of inspectional
observations in a Form FDA-483, warning letter or any other writing; nor has QLT USA or, to
Seller&#146;s Knowledge, any of QLT USA&#146;s Product licensees received any notice from the FDA or any
other Governmental Authority that it has commenced any action to withdraw approval, place material Product-specific sales
or marketing restrictions on or request the recall of any Product, or that it has commenced any
action to enjoin or place material restrictions on the production of any Product.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(g)&nbsp;Since January&nbsp;1, 2007, to Seller&#146;s Knowledge, no officer, employee or agent of QLT USA has
made an untrue statement or a material fact or fraudulent statement to the FDA or any other
Governmental Authority, failed to disclose a material fact required to be disclosed to the FDA or
any other Governmental Authority, or committed an act, made a statement or failed to make a
statement that, at the time such disclosure was made, would reasonably be expected to provide a
basis for the FDA or any other Governmental Authority to invoke its policy respecting &#147;Fraud,
Untrue Statements of Material Facts, Bribery, and Illegal Gratuities,&#148; set forth in 56 Fed. Reg.
46191 (September&nbsp;10, 1991) or any similar policy. QLT USA has not employed or used in any capacity
the services of any individual or entity debarred under 21 U.S.C. &#167; 335a(a) or any similar Laws in
connection with a Product, and neither QLT USA, nor any of their respective directors, officers,
agents or employees, has engaged in any conduct that has resulted, or would reasonably be expected
to result, in debarment under 21 U.S.C. &#167; 335a(a) or any similar Laws.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(h)&nbsp;Neither Seller nor QLT USA nor any of their respective directors, officers, employees or
managers, or, to Seller&#146;s Knowledge, any of the stockholders, distributors, resellers, consultants,
brokers, representatives, agents or other Persons associated with or acting on their behalf has
(a)&nbsp;used any corporate funds for an unlawful contribution, gift, entertainment or other unlawful
expense relating to any political or business activity, (b)&nbsp;used any corporate funds to make any
direct or indirect unlawful payment of money or anything else of value to any official, employee or
Person acting on behalf of any Governmental Authority or any public international organization or
to any political party or campaign, (c)&nbsp;made any direct or indirect unlawful payment of money or
anything else of value to any official, employee or Person acting on behalf of any Entity owned or
controlled by any Governmental Authority or any public international organization, (d)&nbsp;violated any
provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended, any rule or regulation
promulgated thereunder or any similar Law, (e)&nbsp;established or maintained any unlawful or unrecorded
fund of corporate monies or other assets, (f)&nbsp;made any false or fictitious entry on the books of
account of QLT USA or (g)&nbsp;made or received any bribe, rebate, payoff, influence payment, kickback
or other unlawful payment.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#091;*&#093; Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->19<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(i)&nbsp;QLT USA is in compliance in all respects with the United States export laws and
regulations, including the International Traffic in Arms Regulations, the FDA, if applicable, and
the Export Administration Regulations, and including compliance with all regulations, orders and
licensing requirements relating to the exportation or reexportation of goods or technology to any
sanctioned country. Neither QLT USA nor its Subsidiaries have since the Atrix Acquisition Date,
nor are they are currently, transacting business with any Person identified as a Specifically
Designated National or Blocked Person by the Office of Foreign Assets Control of the United States
Department of Treasury or listed on either the Denied Person list or Entity List of the Bureau of
Industry and Security of the United States Department of Commerce.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">4.10 <U>Material Contracts</U>. Section&nbsp;4.10 of the Seller Disclosure Schedule sets forth a
true, correct and complete list of the Material Contracts. True, correct and complete copies of
all Material Contracts have been made available to Purchaser. Each Material Contract is legal,
valid and binding, is in full force and effect and is enforceable in accordance with its terms with
respect to QLT USA and, to the Knowledge of Seller, each other party thereto. Except as otherwise
set forth on Section&nbsp;4.10 of the Seller Disclosure Schedule, there is no existing default or breach
of QLT USA under any Material Contract (or event or condition that, with notice or lapse of time or
both would reasonably be expected to constitute such a default or breach) which
has given, or would reasonably be expected to give, any other Person the right to declare a
default, to exercise any remedy under, or to accelerate the maturity or performance of, or to
cancel or modify or terminate any such Material Contract, and, to the Knowledge of Seller, there is
no such default (or event or condition that, with notice or lapse of time or both, would reasonably
be expected to constitute such default or breach) by any third party that is a party to any
Material Contract. QLT USA has not granted any power of attorney.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">4.11 <U>Financial Statements</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(a)&nbsp;Seller has made available to Purchaser true, correct and complete copies of the audited
consolidated balance sheets and statements of income, changes in stockholders&#146; equity and cash flow
as of and for the fiscal years ended December&nbsp;31, 2006, December&nbsp;31, 2007 and December&nbsp;31, 2008 for
Seller and its Subsidiaries (the &#147;<U>Audited Financial Statements</U>&#148;). Seller has delivered to
Purchaser at the Closing, an unaudited balance sheet and statement of income (including supporting
schedules thereto) as of the Closing Date for QLT USA, which is true, correct and complete with
respect to the line items entitled &#147;Intercompany Note Receivable,&#148; &#147;Intercompany Investment,&#148;
&#147;Goodwill&#148; and &#147;Plant, Property and Equipment&#148; and estimated in good faith with respect to all
other line items (the &#147;<U>Closing Date Financial Statement</U>&#148;). The Audited Financial
Statements (including the notes thereto) each present fairly the consolidated financial position of
Seller and its Subsidiaries, taken as a whole, as of the respective dates thereof and the results
of consolidated operations of Seller and its Subsidiaries, if any, for the fiscal periods therein
set forth. Each of the Audited Financial Statements and the Closing Date Financial Statement has
been prepared in accordance with GAAP as in effect from time to time, consistently and correctly
applied throughout the periods covered thereby, except as may be indicated in the notes thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#091;*&#093; Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->20<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(b)&nbsp;QLT USA maintains a system of internal accounting controls sufficient to provide
reasonable assurance that (i)&nbsp;transactions are executed with management&#146;s authorization, (ii)
transactions are recorded as necessary to permit preparation of financial statements in accordance
with GAAP as in effect from time to time and to maintain accountability for assets, (iii)&nbsp;access to
assets is permitted only in accordance with management&#146;s authorization and (iv)&nbsp;the recorded
accountability for assets is compared with existing assets at reasonable intervals and appropriate
action is taken with respect to any differences.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(c)&nbsp;Seller has provided Purchaser an unaudited consolidated balance sheet of QLT USA as of
August&nbsp;31, 2009 (the &#147;<U>August Balance Sheet</U>&#148;). All trade accounts receivable (excluding
trade accounts receivable for royalties) of QLT USA reflected on the August Balance Sheet arose in
the Ordinary Course of Business, are valid and enforceable claims, and the goods and services sold
and delivered that gave rise to such trade accounts receivable (excluding trade accounts receivable
for royalties) were in all material respects sold and delivered in conformity with all applicable
express and implied warranties, purchase orders, agreements and specifications. To the Knowledge
of Seller, such trade accounts receivable of QLT USA are not subject to any valid defense, offset
or counterclaim.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(d)&nbsp;Notwithstanding the foregoing, except as set forth in the proviso below, Seller does not
make any representation or warranty in this <U>Section&nbsp;4.11</U> or in <U>Section&nbsp;4.12</U> below
with respect to any item related to Tax set forth in the Audited Financial Statements, the Closing
Date Financial Statement, the Closing Date Balance Sheet or the August Balance Sheet; provided that
to the extent an item related to Tax is set forth in the Closing Date Financial Statement, the
Closing Date Balance Sheet or the August Balance Sheet and is not reflected in a Tax Return because
it relates to QLT USA&#146;s 2009 taxable year, such item related to Tax is estimated in good faith;
provided further that in no event is any
representation or warranty made with respect to net operating loss carryforwards, tax credits
and similar tax attributes set forth in the Closing Date Financial Statement, the Closing Date
Balance Sheet or the August Balance Sheet to the extent they relate to periods prior to the Atrix
Acquisition Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">4.12 <U>No Undisclosed Liabilities</U>. Other than Liabilities set forth on the Closing Date Balance Sheet, QLT USA does not have
any Liability required under GAAP to be recorded on the Closing Date Balance Sheet.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">4.13 <U>Employee Benefit and Other Employment Matters</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(a)&nbsp;Other than as set forth in Section&nbsp;4.13(a) of the Seller Disclosure Schedule, QLT USA has
no employees, independent contractors or other service providers. QLT USA is not and has not, at
any time since the Atrix Acquisition Date, been delinquent in payments to any employees,
independent contractors or other service providers for any wages, salaries, commissions, bonuses or
any other form of compensation for any services performed for it (or for its benefit) or amounts
required to be reimbursed to such employee, independent contractor or service provider. QLT USA is
and since the Atrix Acquisition Date has been in material compliance with all applicable Laws
respecting labor, employment, immigration, fair employment practices, terms and conditions of
employment, workers&#146; compensation, occupational safety, plant closings, wages and hours. Since the
Atrix Acquisition Date, QLT USA has withheld, remitted and reported all amounts required by
applicable Laws or by agreement to be withheld, remitted and reported from the wages, salaries and
other payments to employees, independent contractors and other service providers; and QLT USA is
not nor, since the Atrix Acquisition Date, has ever been liable for any arrears of wages or any
penalty for failure to comply with any of the foregoing. QLT USA is not nor, since the Atrix
Acquisition Date, has ever been liable for any payment to any trust or other fund or to any
Governmental Authority, with respect to unemployment compensation benefits, social security or
other benefits or obligations for any employee (other than routine payments made in the Ordinary
Course of Business of QLT USA). There are no pending or, to the Knowledge of Seller, threatened,
claims against QLT USA under any workers&#146; compensation plan or policy or for short-term or
long-term disability. There are no controversies pending or, to the Knowledge of Seller,
threatened, between QLT USA and any former employee, independent contractor or other service
provider of QLT USA, which controversies have or would reasonably be expected to result in an
Action. QLT USA does not owe and, as of the Closing Date, is not required to contribute to any
severance or similar payments or benefits for any current or former service providers.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#091;*&#093; Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->21<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(b)&nbsp;QLT USA does not maintain, sponsor, contribute to or have any Liability with respect to
any &#147;employee benefit plan&#148; as defined in Section&nbsp;3(3) of the Employee Retirement Income Security
Act of 1974, as amended (&#147;<U>ERISA</U>&#148;) or any other plan, policy, program, practice, agreement,
understanding or arrangement (whether written or oral) providing compensation or other benefits to
any current or former director, officer, employee, independent contractor, consultant or other
service provider (or to any dependent or beneficiary thereof) of QLT USA or any ERISA Affiliate (as
defined below), which is now, or was since the Atrix Acquisition Date, maintained, sponsored or
contributed to by QLT USA or any ERISA Affiliate, or under which QLT USA or any ERISA Affiliate has
any obligation or liability, whether actual or contingent, including, without limitation, all
retirement, pension, profit sharing, incentive, bonus, deferred compensation, vacation, holiday,
cafeteria, medical, disability, severance, retention, postretirement, change in control, stock
purchase, stock option, stock appreciation, phantom stock, restricted stock or other stock-based
compensation plans, policies, programs, practices, agreements or arrangements (each a &#147;<U>QLT USA
Benefit Plan</U>&#148;). For purposes of this <U>Section&nbsp;4.13</U>, &#147;<U>ERISA Affiliate</U>&#148; means any
Entity other than QLT USA that, together with QLT USA, is, or at any time
since the Atrix Acquisition Date has been, considered under common control and treated as one
employer under Section&nbsp;414(b), (c), (m)&nbsp;or (o)&nbsp;of the Code.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(c)&nbsp;At all times since the Atrix Acquisition Date during any period in which QLT USA or any
ERISA Affiliate maintained, sponsored, contributed to or had any Liability with respect to any QLT
USA Benefit Plan: (i)&nbsp;all required contributions or payments were timely made, (ii)&nbsp;each such QLT
USA Benefit Plan was operated in material compliance with its terms and applicable Laws, (iii)&nbsp;no
transaction prohibited by ERISA Section&nbsp;406 and no &#147;prohibited transaction&#148; under Section 4975(c)
of the Code occurred, (iv)&nbsp;no action, suit, proceeding, hearing or investigation with respect to
any QLT USA Benefit Plan occurred and (v)&nbsp;each such QLT USA Benefit Plan was terminated in
compliance with its terms and applicable Law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(d)&nbsp;Since the Atrix Acquisition Date, neither QLT USA nor any ERISA Affiliate (i)&nbsp;has ever
maintained, contributed to, or been obligated to contribute to any plan that is subject to Title IV
of ERISA or the minimum funding requirements of Section&nbsp;412 of the Code, (ii)&nbsp;has ever contributed
to, been obligated to contribute to, or incurred any Liability to a multiemployer plan (as defined
in ERISA section 3(37)) or (iii)&nbsp;has ever entered into a collective bargaining agreement or other
union contract.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(e)&nbsp;During the preceding two years, QLT USA has not effectuated a &#147;plant closing&#148; (as defined
under WARN) or a &#147;mass lay-off&#148; (as defined under WARN), in either case affecting any site of
employment or facility of QLT USA, except in accordance with WARN, or has incurred any Liability
under WARN or any similar state or local law that remains unsatisfied.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(f)&nbsp;QLT USA is not a party to any Contract or plan entered into since the Atrix Acquisition
Date that has resulted or would reasonably be expected to result, separately or in the aggregate,
in the payment of (i)&nbsp;any &#147;excess parachute payment&#148; within the meaning of Section&nbsp;280G of the Code
(or any corresponding provision of state, local or foreign Tax law), (ii)&nbsp;any amount that will not
be fully deductible as a result of Section 162(m) of the Code (or any corresponding provision of
state, local or foreign Tax law) or (iii)&nbsp;any amount that would reasonably be expected to cause any
service provider of QLT USA or its Affiliates to be subject to Tax under Section&nbsp;409A of the Code.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#091;*&#093; Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->22<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">4.14
<U>Insurance</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(a)&nbsp;True, correct and complete copies of all insurance policies (including policies providing
property, casualty, liability and workers&#146; compensation coverage and bond and surety arrangements)
to which QLT USA is a party, a named insured, or otherwise the beneficiary of coverage, including
all occurrence-based policies applicable to QLT USA (or the Included Assets), have been made
available to Purchaser.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(b)&nbsp;Each of such insurance policies is legal, valid and binding, is in full force and effect
and is enforceable in accordance with its terms, and all premiums due with respect thereto have
been paid as of the date hereof. There is no existing default or breach of QLT USA or Seller which
would reasonably be expected to give any other Person the right to declare a default, to exercise
any remedy under, or to cancel or modify or terminate, any such insurance policy, and, to the
Knowledge of Seller, there is no such default. To Seller&#146;s Knowledge, such policies are sufficient
to protect the Included Assets and the business of QLT USA against the risks of the sort normally
insured by similar businesses. Since the Atrix Acquisition Date, there has not been any lapse of
coverage with respect to the matters covered by any such policy.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(c)&nbsp;Since the Atrix Acquisition Date, QLT USA has not received any written notice or other
written communication regarding any actual or possible (i)&nbsp;cancellation or invalidation of any
insurance policy, (ii)&nbsp;refusal of any coverage or rejection of any claim under any insurance policy
or (iii)&nbsp;adjustment in the amount of any premium payable with respect to any insurance policy,
except for adjustment in connection with the renewal of such policies. There is no pending or, to
the Knowledge of Seller, threatened claim under any insurance policy that does, or would reasonably
be expected to, result in, individually or in the aggregate, a Material Adverse Effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">4.15 <U>Related Party Transactions</U>. Neither Seller nor any of its Affiliates, directors, officers or Subsidiaries is party to
any Contract with, or is involved in any other business arrangement or relationship with, QLT USA.
Neither Seller nor any of its Affiliates, directors, officers or Subsidiaries owns, leases or
licenses any Asset which is owned, leased or licensed by QLT USA or is used in the operation of
business conducted or proposed to be conducted by QLT USA.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">4.16 <U>Real Property</U>. QLT USA does not own or lease any real property.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>ARTICLE V<BR>
REPRESENTATIONS AND WARRANTIES OF SELLER</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Seller represents and warrants to Purchaser as of the Execution Date as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">5.1 <u> Organization; Due Authorization</U>. Seller is a corporation duly organized and validly existing under the laws of the Province
of British Columbia, Canada. Seller has all requisite corporate power and authority to execute,
deliver and perform its obligations under this Agreement and the Other Transaction Documents to
which it is, or is specified to become, a party and to consummate the transactions contemplated
hereby and thereby. The execution and delivery of this Agreement and the Other Transaction
Documents to which it is, or is specified to become, a party and the performance of all of its
obligations hereunder and thereunder have been duly authorized by Seller.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#091;*&#093; Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->23<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">5.2 <U>No Conflicts; Enforceability</U>. The execution, delivery and performance of this Agreement and the Other Transaction
Documents and the consummation of the transactions contemplated hereby and thereby (a)&nbsp;are not
prohibited or limited by, do not and will not violate or contravene, do not and will not conflict
with, and do not and will not result in the breach of or a default under, any provision of the
articles or other governing documents of Seller, (b)&nbsp;assuming all of the consents, approvals,
authorizations and permits required by this Transaction have been obtained and all the filings and
notifications required by this Transaction have been made and any waiting periods thereunder have
terminated or expired, do not and will not conflict with any Law to which Seller is subject or by
which Seller is bound, (c)&nbsp;do not and will not violate or contravene, conflict with, result in a
breach of, constitute (with or without due notice or lapse of time or both) a default under, result
in the acceleration of obligations under, create in any party the right to terminate, modify or
cancel, or require any notice, consent or waiver under, (i)&nbsp;any Contract to which Seller is a party
or by which Seller is bound or (ii)&nbsp;any award, judgment, ruling, charge, order, writ, injunction or
decree of any Governmental Authority or arbitrator to which Seller is a party or by which Seller is
bound or (d)&nbsp;except as provided in this Agreement, results in the creation or imposition of any
Encumbrance on any Share of Seller. This Agreement has been duly executed and delivered by
Seller, and constitutes the legal, valid and binding obligation of Seller, enforceable against
Seller in accordance with its terms, except as enforceability may be limited or affected by
applicable bankruptcy, insolvency, moratorium, reorganization or other laws of general application
relating to or affecting creditors&#146; rights generally.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">5.3 <U>Consents</U>. Except for the requisite filings under the HSR Act and the expiration
or termination of the waiting period thereunder, and as may be necessary as a result of any facts
or circumstances relating solely to Seller, no notice to, filing with, authorization of, exemption
by, or consent of, any Person, including any Governmental Authority, is required for Seller to
consummate the Transaction.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">5.4 <U>Litigation</U>. There is no Action pending or, to the Knowledge of Seller, threatened, directly or
indirectly involving Seller (or to the Knowledge of Seller, any third party) that would reasonably
be expected to prohibit, hinder, delay or otherwise impair Seller&#146;s ability to perform its
obligations hereunder or under any Other Transaction Document, would affect the legality, validity
or enforceability of this Agreement or any Other Transaction Document, or prevent or delay the
consummation of the transactions contemplated hereby or thereby.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">5.5 <U>Brokers&#146; Fees</U>. QLT USA is not a party to any agreement with Goldman, Sachs &#038; Co. Other than Goldman,
Sachs &#038; Co., there is no broker, investment banker, agent, finder or other intermediary that has
been retained by, or is authorized to act on behalf of, QLT USA, Seller, any of Seller&#146;s Affiliates
or any of its or their officers or directors, who shall be entitled to any fee, expense
reimbursement, indemnity or commission in connection with this Agreement or any Other Transaction
Document or the consummation of the transactions contemplated hereby or thereby. No such fee,
expense reimbursement, indemnity or commission is or will become a Liability of QLT USA, Purchaser
or any Affiliate of Purchaser.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">5.6 <U>Shares</U>. Seller has good and valid title to all of the Shares, free and clear of any restrictions on
transfer (other than any restrictions under the Securities Act and state securities laws), Taxes,
Encumbrances, options, warrants, purchase rights, rights of first refusal, Contracts of Seller,
equities, claims and demands, in each case other than those arising under this Agreement, and holds
of record and owns beneficially all of the Shares. Seller is not a party to any option, warrant,
purchase right or other Contract that would reasonably be expected to require Seller to sell,
transfer or otherwise dispose of any capital stock of QLT USA (other than this Agreement).
Assuming Purchaser has the requisite power and authority to be the lawful owner of the Shares, upon
delivery to Purchaser at the Closing of one or more certificates representing the Shares, duly
endorsed by Seller or accompanied by duly executed assignment documents, good and valid title to
the Shares will pass to Purchaser, free and clear of any restrictions on transfer (other than any
restrictions under the Securities Act and state securities laws), Taxes, Encumbrances, options,
warrants, purchase rights, rights of first refusal, Contracts of Seller, equities, claims and
demands.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#091;*&#093; Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->24<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">5.7 <U>No Other Representations or Warranties</U>. Seller acknowledges that: (a)&nbsp;except for the representations and warranties of Purchaser
set forth in <U>ARTICLE VI</U>, Seller is not relying and has not relied on any other
representations or warranties
whatsoever regarding the subject matter of this Agreement, express or implied; (b)&nbsp;the
representations and warranties of Purchaser set forth in <U>ARTICLE VI</U> constitute the sole and
exclusive representations and warranties to Seller in connection with the transactions contemplated
by this Agreement; and (c)&nbsp;no other representation or warranty, of any kind or nature, express or
implied, has been made by Purchaser, or by any current or former officer, director, employee,
shareholder, affiliate or advisor of Purchaser; <I>provided, however, </I>that, notwithstanding the
foregoing, nothing in this <U>Section&nbsp;5.7</U> shall relieve any Person of liability for fraud or
intentional misrepresentation.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>ARTICLE VI<BR>
REPRESENTATIONS AND WARRANTIES OF PURCHASER</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Purchaser represents and warrants to Seller as of the Execution Date as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">6.1 <u>Organization; Due Authorization</u>. Purchaser is a corporation duly organized and validly existing and in good standing under
the laws of Delaware. Purchaser has all requisite corporate power and authority to execute, deliver
and perform its obligations under this Agreement and the Other Transaction Documents to which it
is, or is specified to become, a party and to consummate the transactions contemplated hereby and
thereby. The execution and delivery of this Agreement and the Other Transaction Documents to which
it is, or is specified to become, a party and the performance of all of its obligations hereunder
and thereunder have been duly authorized by Purchaser.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">6.2 <U>No Conflicts; Enforceability</U>. The execution, delivery and performance of this Agreement and the Other Transaction
Documents and the consummation of the transactions contemplated hereby and thereby (a)&nbsp;are not
prohibited or limited by, do not and will not violate or contravene, do not and will not conflict
with, and do not and will not result in the breach of or a default under, any provision of the
certificate of incorporation or bylaws of Purchaser, (b)&nbsp;assuming all of the consents, approvals,
authorizations and permits required by this Transaction have been obtained and all the filings and
notifications required by this Transaction have been made and any waiting periods thereunder have
terminated or expired, do not and will not conflict with any Law to which Purchaser is subject or
by which Purchaser is bound, or (c)&nbsp;do not and will not violate or contravene, conflict with,
result in a breach of, constitute (with or without due notice or lapse of time or both) a default
under, result in the acceleration of obligations under, create in any party the right to terminate,
modify or cancel, or require any notice, consent or waiver under, (i)&nbsp;any Contract to which
Purchaser is a party or by which Purchaser is bound or (ii)&nbsp;any award, judgment, ruling, charge,
order, writ, injunction or decree of any Governmental Authority or arbitrator to which Purchaser is
a party or subject or by which Purchaser is bound. This Agreement has been duly executed and
delivered by Purchaser, and constitutes the legal, valid and binding obligation of Purchaser,
enforceable against Purchaser in accordance with its terms, except as enforceability may be limited
or affected by applicable bankruptcy, insolvency, moratorium, reorganization or other laws of
general application relating to or affecting creditors&#146; rights generally.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">6.3 <U>Consents</U>. Except for the requisite filings under the HSR Act and the expiration or termination of the
waiting period thereunder, and as may be necessary as a result of any facts or circumstances
relating solely to Purchaser, no notice to, filing with, authorization of, exemption by, or consent
of, any Person, including any Governmental Authority, is required for Purchaser to consummate the
Transaction.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#091;*&#093; Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.
</DIV>

<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->25<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">6.4 <U>Litigation</U>. There is no Action pending or, to the Knowledge of Purchaser, threatened, directly or
indirectly involving Purchaser (or to the Knowledge of Purchaser, any third party) that would
prohibit, hinder, delay or otherwise impair Purchaser&#146;s ability to perform its obligations
hereunder or under any Other Transaction Document, would affect the legality, validity or
enforceability of this Agreement or any Other Transaction Document, or prevent or delay the
consummation of the transactions contemplated hereby or thereby.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">6.5 <U>Solvency</U>. Immediately after the Closing and after giving effect to the consummation of the
transactions contemplated by this Agreement and the Other Transaction Documents, including the
payment of the portion of the Purchase Price set forth in <U>Section&nbsp;2.2(b)(i)</U> and the payment
of all fees and expenses related to the transactions contemplated by this Agreement and the Other
Transaction Documents, Purchaser will not be insolvent, left with unreasonably small capital,
incurred debts beyond its ability to pay such debts as they mature and the capital of Purchaser
will not be impaired.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">6.6 <U>Securities Act</U>. Purchaser (a)&nbsp;understands that the Shares have not been, and will not be, registered under
the Securities Act, or under any state securities laws, and are being offered and sold in reliance
upon federal and state exemptions for transactions not involving any public offering, (b)&nbsp;is
acquiring the Shares solely for its own account for investment purposes, and not with a view to the
distribution thereof, (c)&nbsp;is a sophisticated investor with knowledge and experience in business and
financial matters, (d)&nbsp;has received certain information concerning QLT USA and has had the
opportunity to obtain additional information as desired in order to evaluate the merits and the
risks inherent in holding the Shares, (e)&nbsp;is able to bear the economic risk and lack of liquidity
inherent in holding the Shares and (f)&nbsp;is an &#147;Accredited Investor&#148; as defined in Regulation&nbsp;D under
the Securities Act and in Canadian National Instrument 45-106.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">6.7 <U>No Other Representations or Warranties</U>. Purchaser acknowledges that: (a)&nbsp;except for the representations and warranties of Seller
set forth in <U>ARTICLE IV</U> or <U>ARTICLE V</U>, Purchaser is not relying and has not relied
on any other representations or warranties whatsoever regarding the subject matter of this
Agreement, express or implied; (b)&nbsp;the representations and warranties of Seller set forth in
<U>ARTICLE IV</U> and <U>ARTICLE V</U> constitute the sole and exclusive representations and
warranties to Purchaser in connection with the transactions contemplated by this Agreement; and (c)
no other representation or warranty, of any kind or nature, express or implied, has been made by
Seller, or by any current or former officer, director, employee, shareholder, affiliate or advisor
of Seller, including as to (i)&nbsp;merchantability or fitness for any particular use or purpose, (ii)
the operation of the Product Line Business by Purchaser after the Closing in any manner other than
as used and operated by QLT USA prior to the Closing or (iii)&nbsp;the probable success or profitability
of the Product or Product Line Business after the Closing; <I>provided, however, </I>that, notwithstanding
the foregoing, nothing in this <U>Section&nbsp;6.8</U> shall relieve any Person of liability for fraud
or intentional misrepresentation.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#091;*&#093; Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->26<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>ARTICLE VII<BR>
COVENANTS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">7.1
<U>Conduct of the Business Post-Closing</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(a)&nbsp;From and after the Closing Date, until such time as payments to Seller in respect of
Post-Closing Royalty Amounts have been paid in full under <U>Section&nbsp;2.2(b)(iii)</U>, Purchaser
shall (i)&nbsp;operate the Product Line Business under the Sanofi Agreement and MediGene Agreement in
substantially the same manner as the Product Line Business was conducted thereunder as of the
Closing Date (provided that the development, manufacture, distribution, marketing, licensing or
sale of a Future Product shall not constitute a failure to operate the Product Line Business under
the Sanofi Agreement or MediGene Agreement, as applicable, in substantially the same manner) and in
compliance with all applicable laws, rules and regulations, (ii)&nbsp;not terminate the Sanofi Agreement
or MediGene Agreement, (iii)&nbsp;not take any action as may cause to be terminated the Sanofi
Agreement or MediGene Agreement, (iv)&nbsp;not amend the Sanofi Agreement or MediGene Agreement in a
manner that could reasonably be expected to adversely affect the likelihood of the payment of the
Post-Closing Royalty Amounts to Seller under <U>Section&nbsp;2.2(b)(iii)</U> and (v)&nbsp;not engage in any
action with the intent to, directly or indirectly, adversely impact or materially delay, or which
would reasonably be expected to have the effect of adversely impacting or materially delaying, the
payment of the Post-Closing Royalty Amounts to Seller under <U>Section&nbsp;2.2(b)(iii)</U>; <I>provided,
however</I>, that (1)&nbsp;the foregoing clauses (i), (iii)&nbsp;and (v)&nbsp;shall not prevent Purchaser from
complying with any order or decree of any Governmental Authority with respect to the Product Line
Business, (2)&nbsp;Purchaser shall not be deemed to have breached the foregoing clause (i)&nbsp;to the extent
its failure to operate the Product Line Business under the Sanofi Agreement and MediGene Agreement
is caused by or results from (A)&nbsp;events beyond the reasonable control of Purchaser, including war
(declared or undeclared), riot, terrorism, political insurrection, fire, snow, flood, explosion,
earthquake or tornadoes or (B)&nbsp;an interruption or delay by any supplier or third party service
provider in the provision of any materials, products or services relevant to the Product Line
Business that results in Purchaser&#146;s inability to sell at least substantially the same quantity of
the Product as was sold prior to the Closing Date, and (3)&nbsp;the foregoing clauses (iii)&nbsp;and (v)
shall not prevent Purchaser from operating the Product Line Business under the Sanofi Agreement and
MediGene Agreement in substantially the same manner as the Product Line Business was conducted
thereunder as of the Closing Date, as required by the foregoing clause (i).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(b)&nbsp;Notwithstanding the foregoing, in the event either the Sanofi Agreement or the MediGene
Agreement is terminated before all of the payments to be made to Seller under <U>Section
2.2(b)(iii)</U> have been made and any other agreement is entered into by Purchaser or an Affiliate
thereof with respect to the Product in the territory set forth in the Sanofi Agreement or the
MediGene Agreement, respectively, or Purchaser or an Affiliate thereof elects to sell the Product
in such territory directly, then Seller and Purchaser shall work together in good faith to
determine the terms pursuant to which the calculation of each payment to be made to Seller under
<U>Section&nbsp;2.2(b)(iii)</U> will be adjusted based on payments received pursuant to any such other
agreement entered into with respect to the Product or from the sale of the Product directly in such
territory by Purchaser or an Affiliate thereof, as applicable. Seller and Purchaser each
acknowledge that it is the intention of the Parties under this Section&nbsp;7.1(b) to agree to
commercially reasonable terms that approximate as much as possible both the frequency and the
amount of the payments that would have been made under Section&nbsp;2.2(b)(iii) if the termination of
the MediGene Agreement or Sanofi Agreement, as applicable, had not occurred.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">7.2 <U>Required Approvals and Consents</U>. The Parties shall make all filings required to be made in order to consummate the
Transaction prior to the Closing. The Parties shall also cooperate with each other with respect to
all filings that Purchaser elects to make. Seller shall, and shall cause QLT USA to, use its
commercially reasonable efforts to obtain all third party consents to be obtained under this
Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#091;*&#093; Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.
</DIV>

<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->27<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">7.3 <U>Further Assurances; Further Documents</U>. On and after the Closing Date, and without additional consideration, each of Purchaser and
Seller shall, at the reasonable request of the other Party, provide assistance to such other Party,
including, but not limited to, executing and delivering to such other Party all such further
instruments, assignments, assurances and other documents as such other Party may reasonably request
in connection with the carrying out of this Agreement and the Transaction. Without limiting the
generality of the foregoing, for a period of twelve (12)&nbsp;months following the Closing Date, Seller
shall: (a)&nbsp;notify Purchaser of any Intellectual Property exclusively related to the Product or
otherwise necessary for the Product Line Business identified by Seller following the Closing Date
as owned, licensed to or otherwise held in whole or in part by Seller or any of its Subsidiaries
and take such action as is reasonably required to enable Purchaser to procure, maintain, perfect
and enforce the full and exclusive benefit, enjoyment, right, title and interest, on a worldwide
basis, in Purchaser&#146;s name and for Purchaser&#146;s benefit, in and to all such Intellectual Property
and (b)&nbsp;to the extent commercially reasonable, make available to Purchaser (or a representative of
Purchaser) during normal business hours and upon reasonable agreed-upon times, to the extent
reasonably requested, personnel employed by Seller at the time of any such request who were
responsible for preparing or maintaining information, records, filings, submissions, responses to
official actions and documents with respect to the QLT USA Intellectual Property prior to the
Closing. Purchaser acknowledges and agrees that for purposes of clause (b)&nbsp;above, as of and
following the Closing Date, QLT USA and its personnel and representatives (and not Seller and its
personnel and representatives) will be responsible for preparing and maintaining all such
information, records, filings, submissions, responses to official actions and documents with
respect to the QLT USA Intellectual Property.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">7.4 <U>Noncompetition</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(a)&nbsp;Except as otherwise explicitly permitted in <U>Section&nbsp;7.4(b)</U>, from the Effective
Time and continuing until the &#091;*&#093; anniversary of the Closing Date (the &#147;<U>Noncompete
Period</U>&#148;), neither Seller nor any of its Affiliates, directly or indirectly through any licensee
thereof, shall (i)&nbsp;engage in any Seller Competitive Activity, or (ii)&nbsp;cause or actively assist any
other Person to engage in any Seller Competitive Activity. Except as otherwise explicitly
permitted in <U>Section&nbsp;7.4(b)</U>, during the Noncompete Period, neither Purchaser nor any of its
Affiliates, directly or indirectly through any licensee thereof, shall (i)&nbsp;engage in any Purchaser
Competitive Activity, or (ii)&nbsp;cause or actively assist any other Person to engage in any Purchaser
Competitive Activity.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(b)&nbsp;If, during the Noncompete Period, Seller or any of its Affiliates acquires an Entity that
engages in any Seller Competitive Activity, or all or substantially all of the assets of an Entity
that engages in any Seller Competitive Activity and such assets include a Seller Competitive
Product, Seller or such Affiliate shall have &#091;*&#093;  from the
acquisition date in which to divest itself of such Seller Competitive Product or to otherwise cease
such Seller Competitive Activity, and Seller shall not be in breach of <U>Section&nbsp;7.4(a)</U> if it
or the Affiliate, as the case may be, so divests such Seller Competitive Product or ceases such
Seller Competitive Activity within such &#091;*&#093; period. If, during the
Noncompete Period, Purchaser or any of its Affiliates acquires an Entity that engages in any
Purchaser Competitive Activity, or all or substantially all of the assets of an Entity that engages
in any Purchaser Competitive Activity and such assets include a Purchaser Competitive Product,
Purchaser or such Affiliate shall have &#091;*&#093; from the acquisition date
in which to divest itself of such Purchaser Competitive Product or to otherwise cease such
Purchaser Competitive Activity, and Purchaser shall not be in breach of <U>Section&nbsp;7.4(a)</U> if
it or the Affiliate, as the case may be, so divests such Purchaser Competitive Product or ceases
such Purchaser Competitive Activity within such &#091;*&#093; period.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#091;*&#093; Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.
</DIV>

<P align="center" style="font-size: 10pt; text-indent: 8%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->28<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(c)&nbsp;Because of the difficulty of measuring economic losses to Purchaser or Seller, as
applicable, as a result of a breach of the restrictive covenants set forth in this <U>Section
7.4</U>, and because of the immediate and irreparable damage that would be caused to Purchaser or
Seller, as applicable for which monetary damages would not be a sufficient remedy, the Parties
agree that Purchaser or Seller, as applicable, will be entitled to seek specific performance,
temporary and permanent injunctive relief, and such other equitable remedies to which it may then
be entitled against Seller or Purchaser, as applicable, or any of its respective Affiliates with
respect to any such breach. This <U>Section&nbsp;7.4</U> shall not limit any other legal or equitable
remedies that Purchaser or Seller, as applicable, may have against Seller or any of its Affiliates
or Purchaser or any of its Affiliates, as applicable, for violation of the restrictions of this
<U>Section&nbsp;7.4</U>. The Parties agree that Purchaser or Seller, as applicable, shall have the
right to seek relief for any violation or threatened violation of this <U>Section&nbsp;7.4</U> by
Seller or any of its Affiliates or Purchaser or any of its Affiliates, as applicable, from any
court of competent jurisdiction in any jurisdiction authorized to grant the relief necessary to
prohibit the violation or threatened violation of this <U>Section&nbsp;7.4</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(d)&nbsp;In no event shall the ownership by Seller (or an Affiliate thereof) or Purchaser (or an
Affiliate thereof) of less than five percent (5%) of the equity securities of a publicly-traded
company constitute a Seller Competitive Activity or a Purchaser Competitive Activity, as
applicable.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">7.5 <U>HSR Fees</U>. Purchaser and Seller have paid the required HSR Act filing fees, with
each of Purchaser and Seller paying one-half of such filing fees.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">7.6 <U>Product Reports</U>. From and after the Closing Date, until such time as payments to
Seller in respect of Post-Closing Royalty Amounts have been paid in full under <U>Section
2.2(b)(iii)</U>, Purchaser shall furnish to Seller (i)&nbsp;a copy of the quarterly written report
required to be furnished to QLT USA by Section&nbsp;4.05(a) of the Sanofi Agreement and Section&nbsp;4.05(a)
of the MediGene Agreement, respectively, promptly following the date on which such report is
furnished to QLT USA and (ii)&nbsp;any other written report received with respect to the Post-Closing
Royalty Amounts from Sanofi or MediGene.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">7.7 <U>Name Change</U>. Promptly following the Closing (and in any event within 30 calendar
days following the Closing), Purchaser shall take all actions reasonably necessary to change the
QLT USA name to a name that does not include the word &#147;QLT&#148; or any variation thereof. Thereafter,
Purchaser shall use its commercially reasonable efforts to cease using the QLT USA name and shall
promptly file or cause to be filed (and in any event within one year following the Closing shall
have filed or caused to be filed), on behalf of QLT USA, any and all documents required to be filed
to reflect the name change with each applicable Governmental Authority, including patent and
trademark authorities.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>ARTICLE VIII<BR>
CONDITIONS TO CLOSING</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">8.1 <U>Conditions Precedent to Obligations of Purchaser and Seller</U>. At or prior to the Closing Date:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(a)&nbsp;<U>Litigation</U>. No preliminary or permanent injunction or other order has been issued
by any court or by any Governmental Authority, body or authority which enjoins, restrains,
prohibits or makes illegal pursuant to applicable Law the Transaction on the Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(b)&nbsp;<U>HSR Act</U>. Any waiting period (and any extension thereof) under the HSR Act or any
foreign equivalent applicable to the Transaction has expired.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(c)&nbsp;<U>Excluded Assets and Excluded Liabilities</U>. The Excluded Assets and Excluded
Liabilities are no longer held by QLT USA.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#091;*&#093; Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.
</DIV>

<P align="center" style="font-size: 10pt; text-indent: 8%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->29<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>ARTICLE IX<BR>
ADDITIONAL COVENANTS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">9.1 <U>Confidentiality; Publicity</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(a)&nbsp;The terms of the Confidentiality Agreement shall apply to any information provided to
Seller or Purchaser pursuant to the Transaction or this Agreement, including information provided
to Purchaser pursuant to <U>Section&nbsp;7.1</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(b)&nbsp;No Party shall make any press release concerning the Transaction unless all Parties
jointly agree upon its necessity and content. Any other publication, news release or other public
announcement by a Party relating to this Agreement or to the performance hereunder shall first be
reviewed and consented to in writing by the other Party; <I>provided, however</I>, that notwithstanding
any contrary term contained in the Confidentiality Agreement, (i)&nbsp;any disclosure that is required
by Law as advised by the disclosing Party&#146;s counsel may be made without the prior written consent
of the other Party, (ii)&nbsp;a disclosing Party may make disclosure regarding subject matter of this
Agreement or the Transaction to its employees, consultants, collaborators, licensees, CROs,
business partners, investors, potential investors, acquirors and potential acquirors, <I>provided</I>
that, in the case of this clause (ii), the disclosing Party, prior to making such disclosure to any
third party (other than employees), consults with the other Party and provides the other Party an
opportunity to provide reasonable input regarding the process and content of such disclosure and
(iii)&nbsp;any Party may issue a press release or public announcement if the contents of such press
release or public announcement have previously been made public other than through a breach of this
Agreement by the issuing Party, without the prior written consent of the other Party.
Notwithstanding any contrary term contained in the Confidentiality Agreement, to the extent that
any Party determines that this Agreement, a summary thereof or a notification thereof is required
to be registered or filed to comply with the requirements of an applicable stock exchange or
exchange regulation or any Governmental Authority, including the SEC, such Party shall give at
least two (2)&nbsp;Business Days advance written notice of any such required disclosure to the other
Party. Prior to making any such filing, registration or notification, the Parties shall consult
with respect thereto regarding confidentiality. The Parties shall cooperate, each at its own
expense, in such filing, registration or notification, including any confidential treatment
request, and shall execute all documents reasonably required in connection therewith.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">9.2 <U>Availability of Records</U>. After the Closing, Purchaser shall make available to Seller and its Affiliates and
Representatives during normal business hours when reasonably requested, all Product Records in its
possession and shall preserve all such information, records and documents until the later of: (i)
six (6)&nbsp;years after the Closing; (ii)&nbsp;the expiration of all statutes of limitations for assessing
or collecting Taxes for periods ending on or prior to the Closing and periods including the Closing
Date, including extensions thereof applicable to Seller (to the extent Seller has notified
Purchaser thereof) or Purchaser; or (iii)&nbsp;the required retention period under any applicable Law
for all such information, records or documents (it being understood that the Parties shall not be
required to provide any Tax Return to any Person, other than as required by applicable Law or as
otherwise set forth in this Agreement). Purchaser and Seller, to
the extent it is commercially reasonable, shall also make available to each other during
normal business hours, when reasonably requested, personnel responsible for preparing or
maintaining information, records and documents, in connection with Tax matters, governmental
Contracts, litigation or potential litigation, each as it relates to the Included Assets or
Included Liabilities prior to the Closing Date (with respect to Seller) or from and after the
Closing Date (with respect to Purchaser), including product liability and general insurance
liability.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#091;*&#093; Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->30<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">9.3 <U>Regulatory Matters</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(a)&nbsp;From and after the Closing Date, Purchaser, at its cost, shall be solely responsible and
liable for (i)&nbsp;taking all actions, paying all fees and conducting all communication with the
appropriate Governmental Authority required by the Act and other applicable Law in respect of the
Registrations and any transfer thereof, including preparing and filing all reports (including
adverse drug experience reports) or other documentation with the appropriate Governmental Authority
(whether the Product is sold before or after transfer of such Registrations), (ii)&nbsp;taking all
actions and conducting all communication with third parties with respect to Product sold pursuant
to such Registrations (whether sold before or after transfer of such Registrations), including
documenting and responding to all complaints in respect thereof, including complaints related to
tampering, contamination or other adulteration and (iii)&nbsp;investigating and resolving all complaints
and adverse drug experiences with respect to Product sold pursuant to such Registrations (whether
sold before or after transfer of such Registrations).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(b)&nbsp;From and after the Closing Date, Seller shall use commercially reasonable efforts to
notify Purchaser within three (3)&nbsp;Business Days if Seller receives a complaint or information
related to an adverse drug experience with respect to the Product. In addition, Seller shall use
commercially reasonable efforts to assist Purchaser in connection with the investigation of and
response to any complaint or adverse drug experience related to Product sold by Seller.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">9.4 <U>Tax Matters</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(a)&nbsp;Except as provided in <U>Section&nbsp;9.4(b)</U>, Purchaser shall prepare or cause to be
prepared and file or cause to be filed all Tax Returns for QLT USA that relate to taxable periods
or portions thereof ending on or before the Closing Date that are due after the Closing Date and
have not been filed prior to the Closing, on a basis consistent with past practice (except as may
be required by Law). Prior to filing any Tax Returns described in this <U>Section&nbsp;9.4(a)</U> for
periods or portions thereof beginning prior to the Closing Date, Purchaser shall deliver to Seller
a draft of each such Tax Return and the associated work papers at least thirty (30)&nbsp;days prior to
the date such Tax Return is to be filed, and shall permit Seller to review and comment on such Tax
Returns and shall make such revisions to such Tax Returns as are reasonably requested by Seller.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(b)&nbsp;Notwithstanding <U>Section&nbsp;9.4(a)</U>, Seller shall prepare or cause to be prepared,
prior to the Closing Date and on a basis consistent with past practice (except as may be required
by Law), all U.S. federal, state, local and foreign income Tax Returns for QLT USA that are due
(taking into account all applicable extensions) after the Closing Date and have not been filed
prior to the Closing and that relate to taxable periods ending on or before December&nbsp;31, 2008 and
shall deliver any such Tax Return to Purchaser at least thirty (30)&nbsp;days prior to the date such Tax
Return is to be filed. Purchaser shall timely file or cause to be filed such Tax Returns. If,
prior to filing, Purchaser desires to make any revisions to any such Tax Return as prepared by
Seller, then Purchaser shall deliver to Seller any such revisions and
the associated work papers at least twenty (20)&nbsp;days prior to the date such Tax Return is to
be filed for Seller&#146;s review and approval, which Seller shall consider in good faith.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(c)&nbsp;The Parties shall cooperate fully, as and to the extent reasonably requested by another
Party, in connection with the filing of Tax Returns pursuant to this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(d)&nbsp;All Transfer Taxes, if any, shall be paid by Purchaser when due. Purchaser will, at its
own expense, file all necessary Tax Returns and other documentation with respect to all such
Transfer Taxes. If required by applicable Law and requested by Purchaser, Seller will, and will
cause its Affiliates to, join in the execution of any such Tax Returns and other documentation.
Purchaser shall provide Seller with evidence reasonably satisfactory to Seller that such Transfer
Taxes have been paid by Purchaser.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#091;*&#093; Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->31<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(e)&nbsp;At such time as reasonably requested by Purchaser, Seller shall execute and deliver to
Purchaser a completed replacement IRS Form W-8BEN, completed by Seller as reasonably requested by
Purchaser to establish that the payments by Purchaser to Seller pursuant to <U>Sections
2.2(b)(ii)</U> and <U>2.2(b)(iii)</U> (the &#147;Deferred Payments&#148;) are exempt from withholding.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(f)&nbsp;Purchaser agrees to take no position on any Tax Return or otherwise that is inconsistent
with treating the payments by Purchaser to Seller hereunder (including the Deferred Payments) as
payments for the Shares, which payments are not subject to withholding under current applicable
United States Tax Law, other than any imputed interest (to the extent required by Law) with respect
to the Deferred Payments, which interest would be exempt from withholding provided Seller delivers
an IRS Form W-8BEN in accordance with <U>Section&nbsp;3.2(a)(ii)</U> or <U>9.4(e)</U>, as applicable.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>ARTICLE X<BR>
TERMINATION</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">10.1 <U>Termination</U>. This Agreement may be terminated at any time by mutual written consent of Purchaser and
Seller.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">10.2 <U>Automatic Termination</U>. Unless terminated pursuant to <U>Section&nbsp;10.1</U>, this Agreement shall continue in full force
and effect until the earlier of (i)&nbsp;such time as Purchaser is no longer obligated to make any
payment of the Purchase Price pursuant to <U>Section&nbsp;2.2(b)(iii)</U> and (ii)&nbsp;the fifteenth
(15<SUP style="font-size: 85%; vertical-align: text-top">th</SUP>) anniversary of the Closing Date, if the cumulative Post-Closing Royalty Amounts
paid to QLT USA and/or any successor or permitted assignee thereto (as set forth in <U>Section
2.2(b)(iii)</U>), up to and including such anniversary date, is less than $250.0&nbsp;million, at which
point this Agreement shall automatically terminate, except with respect to any rights that shall
have accrued prior to such termination; <I>provided, however, </I>that if this Agreement is terminated
pursuant to the preceding clause (i)&nbsp;due to a prepayment by Purchaser as permitted under
<U>Section&nbsp;2.2(c)</U>, such termination shall not affect in any way any period of time under
<U>ARTICLE XI</U> or any right of Purchaser under <U>ARTICLE XI</U>, and such time periods and
such rights shall remain in effect until otherwise terminated in accordance with their respective
terms. Termination of this Agreement shall not relieve any party of liability in respect of
breaches under this Agreement by any party on or prior to termination.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">10.3 <U>Consequences of Termination</U>. Termination of this Agreement pursuant to this <U>ARTICLE X</U> shall terminate all outstanding
obligations and liabilities among the Parties arising from this Agreement except those described
in: (i) <U>Sections&nbsp;9.1</U>, this <U>ARTICLE X</U>, <U>ARTICLE XI</U> and <U>ARTICLE XII</U>;
(ii)&nbsp;the Confidentiality Agreement; and (iii)&nbsp;any other provisions of this Agreement which by their
nature are intended to survive any such termination.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#091;*&#093; Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.
</DIV>

<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->32<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>ARTICLE XI<BR>
SURVIVAL; INDEMNIFICATION</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">11.1 <U>Survival of Representations and Warranties and Covenants</U>. The representations, warranties and covenants contained herein shall survive the Effective
Time for the applicable respective periods set forth in this <U>Section&nbsp;11.1</U> (each a
&#147;<U>Survival Period</U>&#148;), and any and all claims and causes of action for indemnification under
this <U>ARTICLE XI</U> arising out of the inaccuracy or breach of any representation, warranty or
covenant of a Party must be made prior to the termination of the applicable Survival Period. If a
notice for indemnification is given, the Survival Period for such claim shall continue until the
claim is fully resolved. The Parties agree that all of the representations, warranties and
covenants of the Parties contained in this Agreement and any and all claims and causes of action
for indemnification under this <U>ARTICLE XI</U> shall survive as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(a)&nbsp;all representations and warranties of the Parties set forth in <U>ARTICLE IV</U> (other
than <U>Sections&nbsp;4.3</U> and <U>4.8)</U>, <U>ARTICLE V</U> (other than <U>Sections&nbsp;5.1, 5.2</U>
and <U>5.6)</U> and <U>ARTICLE VI</U> (other than <U>Sections&nbsp;6.1</U> and <U>6.2</U>) shall
survive for twelve (12)&nbsp;months after the Closing Date, all representations and warranties of the
Parties set forth in <U>Sections&nbsp;4.3, 5.1, 5.2, 5.6, 6.1</U> and <U>6.2</U> shall survive until
the expiration of the applicable statute of limitations period and the representations and
warranties set forth in <U>Section&nbsp;4.8</U> shall survive until the earlier of (i)&nbsp;the expiration
of the applicable statute of limitations and (ii)&nbsp;five (5)&nbsp;years after the Closing Date;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(b)&nbsp;all covenants, agreements and obligations required to be performed at or before the
Effective Time shall terminate at the Effective Time, if so performed, otherwise they shall survive
until performed;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(c)&nbsp;except as otherwise provided herein, all post-Closing covenants of Purchaser and Seller
shall survive until performed; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(d)&nbsp;any claim for or based on any intentional or willful misrepresentation in any
representation or warranty of Seller in this Agreement or any Other Transaction Document or
involving fraud or willful misconduct shall survive indefinitely from and after the Effective Time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">11.2 <U>Indemnification</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 8%">(a)&nbsp;Subsequent to the Closing, subject to the limitations described in <U>Section&nbsp;11.5</U>:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 8%; text-indent: 4%">(i)&nbsp;Seller shall indemnify and reimburse Purchaser, for itself and on behalf of
its respective Affiliates and each of their respective officers, directors,
employees, stockholders and agents, (the &#147;<U>Purchaser Indemnified Parties</U>&#148;)
from and against any and all damages, claims, losses, costs, liabilities or
expenses, including interest, penalties, reasonable attorneys&#146; fees and expenses of
investigation, response action, removal action or remedial action (collectively,
&#147;<U>Damages</U>&#148;) asserted against, suffered, sustained, accrued or incurred by
such Purchaser Indemnified Party arising out of or relating to (A)
any breach of any representation or warranty made by Seller in this Agreement
or in any certificate delivered to Purchaser at Closing; (B)&nbsp;any failure to perform
any covenant made by, or any obligation of, Seller in or pursuant to this Agreement;
(C)&nbsp;any Excluded Asset or (D)&nbsp;any Excluded Liability.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 8%; text-indent: 4%">(ii)&nbsp;Purchaser shall indemnify and reimburse Seller, for itself and on behalf
of its respective Affiliates and each of their respective officers, directors,
employees, stockholders and agents, (the &#147;<U>Seller Indemnified Parties</U>&#148; and
collectively with the Purchaser Indemnified Parties, the &#147;<U>Covered Parties</U>&#148;)
from and against any and all Damages asserted against, suffered, sustained, accrued
or incurred by such Seller Indemnified Party arising out of or relating to (A)&nbsp;any
breach of any representation or warranty made by Purchaser in this Agreement or in
any certificate delivered to Seller at Closing; (B)&nbsp;any failure to perform any
covenant made by, or any obligation of, Purchaser in or pursuant to this Agreement;
(C)&nbsp;any Included Asset, with respect to any claims arising following the Closing; or
(D)&nbsp;any Included Liability, with respect to any claims arising following the
Closing.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#091;*&#093; Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->33<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(b)&nbsp;The term &#147;Damages&#148; as used in this <U>ARTICLE XI</U> is not limited to matters asserted
by third Persons against the Covered Parties, but includes Damages incurred or sustained by such
Persons in the absence of third-Person claims, and payments by a Covered Party shall not be a
condition precedent to recovery. The amount of any Damages under this <U>ARTICLE XI</U> sustained
by a Covered Party shall be reduced by any amount received by such Covered Party with respect
thereto under any insurance coverage and by the amount of any Tax benefit realized by such Covered
Party in the year of the indemnification payment with respect to the Damages (which realization,
for the avoidance of doubt, shall not include an increase in tax attributes to the extent such
attributes cannot be utilized in such year). The Covered Parties shall use commercially reasonable
efforts to collect any amounts available under such insurance coverage and to realize any such Tax
benefit with respect to the Damages. In addition, if at any time subsequent to any indemnification
payment made pursuant to this <U>ARTICLE XI</U>, a Covered Party realizes a Tax benefit or
receives an amount under insurance coverage with respect to Damages sustained, then such Covered
Party shall promptly reimburse the applicable Indemnifying Party for any payment made or expense
incurred by such Indemnifying Party in connection with providing such indemnification up to such
amount realized or received by the Covered Party (but not in excess of the indemnification payments
actually received from the Indemnifying Party in connection therewith). In furtherance of the
foregoing (and, for the avoidance of doubt, without duplication of any reimbursement pursuant to
the preceding sentence), following an indemnity payment pursuant to this <U>ARTICLE XI</U> by
Seller to a Purchaser Indemnified Party, to the extent the Damages giving rise to such payment
result in a new or increased tax attribute (including, without limitation, a net operating loss
carryforward) that may be utilized to reduce taxable income of such Purchaser Indemnified Party or
an Affiliate thereof in a later taxable period:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 8%; text-indent: 4%">(i)&nbsp;to the extent the timing of the utilization of such attribute is
discretionary, in determining when the Tax benefit is realized for purposes of this
Section&nbsp;11.2(b), such attribute shall be deemed to have been utilized at the
earliest permissible time, and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 8%; text-indent: 4%">(ii)&nbsp;if such Damages equal or exceed $1.0&nbsp;million, such Purchaser Indemnified
Party shall (or shall cause such Affiliate to) provide Seller or Seller&#146;s designated
representative with access to review from time to time as reasonably requested by
Seller all relevant Tax Returns and financial information of such Purchaser
Indemnified Party or Affiliate until such time as such attributes have been utilized
or have expired.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(c)&nbsp;Nothing in this Agreement shall limit any Covered Party&#146;s obligation under applicable law
to mitigate the amount of any Damages for which it is entitled to seek indemnification under this
<U>ARTICLE XI</U>, and the Indemnifying Party shall not be required to make any payment to a
Covered Party in respect of such Damages to the extent such Covered Party has failed to comply with
such obligation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">11.3 <U>Notice of Claims</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(a)&nbsp;Any Party seeking indemnification hereunder (the &#147;<U>Indemnified Party</U>&#148;) shall,
within the Survival Period, give to the Party which is obligated pursuant to this <U>ARTICLE
XI</U> to provide indemnification as set forth herein (the &#147;<U>Indemnifying Party</U>&#148;) a notice
(a &#147;<U>Claim Notice</U>&#148;) describing in reasonable detail the facts giving rise to any claims for
indemnification hereunder and shall include in such Claim Notice (if then known) the amount or the
method of computation of the amount of such claim, and a reference to the provision of this
Agreement or any agreement, certificate or instrument executed pursuant hereto or in connection
herewith upon which such claim is based; <I>provided</I>, that a Claim Notice in respect of any claim in
law or equity by or against a third Person as to which indemnification will be sought shall be
given promptly after the claim is commenced; and <I>provided further</I>, that failure to give such notice
shall not affect such Indemnified Party&#146;s right to indemnification hereunder except to the extent
the Indemnifying Party shall have been materially prejudiced by such failure.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#091;*&#093; Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.
</DIV>

<P align="center" style="font-size: 10pt; text-indent: 8%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(b)&nbsp;The Indemnifying Party shall have thirty (30)&nbsp;days after receipt of any Claim Notice
pursuant hereto to (i)&nbsp;agree to the amount or method of determination set forth in the Claim Notice
to pay such amount to the Indemnified Party in immediately available funds or (ii)&nbsp;to provide such
Indemnified Party with notice that they disagree with the amount or method of determination set
forth in the Claim Notice (the &#147;<U>Dispute Notice</U>&#148;) and thereafter comply with the dispute
resolution provisions set forth in <U>Section&nbsp;11.3(c)</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(c)&nbsp;If the Indemnifying Party provides a Dispute Notice, Purchaser and Seller agree to hold a
meeting, attended by the Chief Executive Officer or President of each Party, or their executive
level designees, to attempt in good faith to attempt to resolve the matters raised in such Dispute
Notice. If, within fifteen (15)&nbsp;days after such initial meeting, the Parties have not succeeded in
negotiating a resolution of the matters raised in such Dispute Notice, such matters shall be
submitted to final and binding arbitration under the then current Commercial Arbitration Rules of
the American Arbitration Association (&#147;<U>AAA</U>&#148;) relating to voluntary arbitrations, as more
fully set forth in <U>Section&nbsp;12.8</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">11.4 <U>Third Person Claims</U>. If a claim by a third Person is made against a Covered Party, and if the relevant
Indemnified Party intends to seek indemnity with respect thereto under this <U>ARTICLE XI</U>,
such Indemnified Party shall promptly notify the Indemnifying Party in writing of such claims,
setting forth such claims in reasonable detail. The Indemnifying Party shall be relieved of their
indemnification obligations hereunder to the extent that a Claim Notice is not delivered promptly
and the Indemnifying Party is materially prejudiced thereby. The Indemnifying Party shall have
twenty (20)&nbsp;days after receipt of such Claim Notice to deliver to the Indemnified Party a written
acknowledgement that such claim is an indemnifiable claim under this <U>ARTICLE XI</U>, that it
will undertake, conduct and control (in accordance with the terms hereof), through counsel of their
own choosing (<I>provided </I>that such counsel must be reasonably acceptable to the Indemnified Party)
and at their own expense, the settlement or defense thereof, and the Indemnified Party shall
cooperate with them in connection therewith; <I>provided </I>that the Indemnified Party may participate in
such settlement or defense through counsel chosen by such
Indemnified Party and paid at its own expense, <I>provided further </I>that, if in the reasonable
opinion of counsel for Indemnifying Party, there is a reasonable likelihood of a conflict of
interest between the Indemnifying Party and the Indemnified Party, the Indemnifying Party shall be
responsible for reasonable fees and expenses of one counsel to such Indemnified Party in connection
with such defense. So long as the Indemnifying Party is reasonably contesting any such claim in
good faith, the Indemnified Party shall not pay or settle any such claim without the consent of the
Indemnifying Party. If the Indemnifying Party does not notify the Indemnified Party within thirty
(30)&nbsp;days after receipt of the Indemnified Party&#146;s Claim Notice hereunder that it elects to
undertake the defense thereof, the Indemnified Party shall have the right to undertake, at the
Indemnifying Party&#146;s cost, risk and expense, the defense, compromise or settlement of the claim but
shall not thereby waive any right to indemnity therefor pursuant to this Agreement. The
Indemnifying Party shall not, except with the consent of the Indemnified Party, enter into any
settlement that is not exclusively monetary and shall be paid entirely by the Indemnifying Party
and does not include as an unconditional term thereof the giving by the Person or Persons asserting
such claim to all Covered Parties of an unconditional release from all liability with respect to
such claim or consent to entry of any judgment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#091;*&#093; Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.
</DIV>

<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->35<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">11.5 <U>Limitation on Indemnity</U>. Notwithstanding anything expressed or implied in this <U>ARTICLE XI</U> to the contrary,
no Indemnified Party shall be entitled to make a claim for indemnification pursuant to <U>Sections
11.2(a)(i)(A)</U> or <U>11.2(a)(ii)(A)</U> of this Agreement unless and until the aggregate of all
Damages suffered by such Indemnified Party and its applicable Covered Parties hereunder exceeds
$150,000 (the &#147;<U>Basket Amount</U>&#148;), whereupon, <I>provided </I>the other requirements of this
<U>ARTICLE XI</U> have been complied with, all subsequent Damages (not including the Basket
Amount) shall become due and payable. Notwithstanding the foregoing, no Basket Amount shall apply
to any Indemnified Party&#146;s claim for indemnification hereunder to the extent such claim results
from (a)&nbsp;any breach of a representation or warranty of Seller set forth in <U>Section&nbsp;4.3</U>
(Capitalization), <U>5.1</U> (Organization; Due Authorization), <U>5.2</U> (No Conflicts;
Enforceability), <U>5.5</U> (Brokers&#146; Fees), or <U>5.6</U> (Shares), (b)&nbsp;any breach of any
representation or warranty of Purchaser set forth in <U>Sections&nbsp;6.1</U> (Organization; Due
Authorization) or <U>6.2</U> (No Conflicts; Enforceability), or (c)&nbsp;any intentional or willful
misrepresentation or fraud. In calculating the amount of Damages of the Covered Parties, if the
Damages for a claim, together with all other Damages for any other claim(s) arising out of the same
or similar events, facts or circumstances or series of related events, facts or circumstances,
total less than $20,000, such Damages shall be excluded in their entirety (and such items shall not
be aggregated for purposes of calculating the Basket Amount), and no Indemnified Party shall have
any recourse against any Indemnifying Party for such Damages. Notwithstanding anything express or
implied in this <U>ARTICLE XI</U> to the contrary, (1)&nbsp;the aggregate liability of Seller or
Purchaser, as the case may be, to an Indemnified Party with respect to any and all Damages arising
under any breach of any representation or warranty (other than as set forth in <U>Section&nbsp;4.8</U>
(Taxes), with respect to which the following clause (2)&nbsp;shall apply, or in <U>Sections&nbsp;4.3</U>
(Capitalization), <U>5.1</U> (Organization; Due Authorization), <U>5.2</U> (No Conflicts;
Enforceability), <U>5.5</U> (Brokers&#146; Fees), <U>5.6</U> (Shares), <U>6.1</U> (Organization; Due
Authorization) or <U>6.2</U> (No Conflicts; Enforceability) or any intentional or willful
misrepresentation, with respect to which the following clause (3)&nbsp;shall apply or any fraud, with
respect to which the following clause (4)&nbsp;shall apply) made by Seller or Purchaser, as the case may
be, in this Agreement or in any certificate delivered to Purchaser or Seller, as the case may be,
at Closing shall not exceed ten percent (10%) of the amount actually paid to Seller pursuant to
<U>Sections&nbsp;2.2(b)</U> and<U> 2.2(c)</U> of this Agreement (the &#147;<U>10% Indemnity Cap</U>&#148;), (2)
the aggregate liability of Seller to an Indemnified Party with respect to any and all Damages
arising under any breach of any representation or warranty set forth in <U>Section&nbsp;4.8</U> (Taxes)
made by Seller in this Agreement shall not exceed fifteen percent (15%) of the amount actually paid
to Seller pursuant to <U>Sections&nbsp;2.2(b)</U> and<U> 2.2(c)</U> of this Agreement (the &#147;<U>15%
Indemnity Cap</U>&#148;), (3)&nbsp;the aggregate liability of Seller or Purchaser, as the case may be, to an
Indemnified Party with respect to any and all Damages arising under any breach of any
representation or warranty set forth in <U>Sections&nbsp;4.3</U>
(Capitalization), <U>5.1</U> (Organization; Due Authorization), <U>5.2</U> (No Conflicts;
Enforceability), <U>5.5</U> (Brokers&#146; Fees), <U>5.6</U> (Shares), <U>6.1</U> (Organization; Due
Authorization) or <U>6.2</U> (No Conflicts; Enforceability) made by Seller or Purchaser, as the
case may be, in this Agreement or any intentional or willful misrepresentation shall be limited to
the amount actually paid to Seller pursuant to <U>Sections&nbsp;2.2(b)</U> and<U> 2.2(c)</U> of this
Agreement and (4)&nbsp;the aggregate liability of Seller or Purchaser, as the case may be, to an
Indemnified Party with respect to any and all Damages arising from fraud shall not be limited. The
10% Indemnity Cap and 15% Indemnity Cap shall be cumulative, such that to the extent Damages are
paid under the 10% Indemnity Cap, the 15% Indemnity Cap shall be reduced by the amount of such
Damages, so that in no event shall the amount of Damages paid with respect to any breach of any
representation or warranty set forth in <U>Section&nbsp;4.8</U> (Taxes) made by Seller in this
Agreement, when aggregated with Damages paid with respect to any breach of any representation or
warranty set forth in <U>ARTICLE IV</U> or <U>ARTICLE V</U> (other than <U>Sections&nbsp;4.3</U>
(Capitalization), <U>5.1</U> (Organization; Due Authorization), <U>5.2</U> (No Conflicts;
Enforceability), <U>5.5</U> (Brokers&#146; Fees), <U>5.6</U> (Shares)) or any intentional or willful
misrepresentation or fraud), exceed fifteen percent (15%) of the amount actually paid to Seller
pursuant to <U>Sections&nbsp;2.2(b)</U> and<U> 2.2(c)</U> of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">11.6 <U>Remedies</U>. The remedies in this <U>ARTICLE XI</U> shall be the sole and exclusive remedies of the
parties with respect to any breach of the respective representations, warranties, covenants and
agreements pursuant to this Agreement or otherwise arising out of this Agreement, regardless of the
theory or cause of action pled, except for the remedies of specific performance, injunction and
other equitable relief; <I>provided, however</I>, that no Party hereto shall be deemed to have waived any
right, claim, cause of action or remedy if and to the extent actual fraud is proven on the part of
a Party by another Party hereto or such right, claim, cause of action or remedy may not be waived
under applicable Law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#091;*&#093; Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.
</DIV>

<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;
<P align="center" style="font-size: 10pt"><!-- Folio -->36<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">11.7 <U>Limitation on Liabilities</U>. Notwithstanding anything herein to the contrary, no Person shall, in any event, be liable
under this <U>ARTICLE XI</U> to any other Person for, and the term &#147;Damages&#148; shall not include,
any consequential, incidental, indirect, special or punitive damages suffered or alleged to be
suffered by such other Person; <I>provided, however</I>, that if any Covered Party is required to
indemnify or otherwise pay any third party that is not a Covered Party for any of the foregoing
items, the foregoing limitation shall not prevent the applicable Party from seeking indemnification
therefor under this Agreement so long as such Party is entitled to be indemnified for such payment
pursuant to Section&nbsp;11.2.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">11.8 <U>Knowledge</U>. Seller acknowledges that the Purchaser Indemnified Parties&#146; rights to
indemnification for any breach of representation, warranty, covenant or obligation of Seller
contained in this Agreement, and the rights and remedies that may be exercised by any Purchaser
Indemnified Party, are part of the basis of the bargain contemplated by this Agreement, and the
Purchaser Indemnified Parties&#146; rights to indemnification under this Agreement shall not be limited,
waived or otherwise affected by virtue of (and Purchaser shall be deemed to have relied on the
express representations and warranties set forth in this Agreement) any knowledge on the part of
Purchaser of any inaccuracy of any such representation or warranty of Seller set forth in this
Agreement, regardless of whether such knowledge was obtained through Purchaser&#146;s own investigation
or otherwise (including disclosure by Seller or any of its Representatives), and regardless of
whether such knowledge was obtained before or after the execution and delivery of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">11.9 <U>No Set-off</U>. Neither Seller, on the one hand, nor Purchaser, on the other hand, shall have any right to
set-off any Damages under this <U>ARTICLE XI</U> against any payments to be made by such Party or
Parties pursuant to this Agreement or any other agreement among the Parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">11.10 <U>Treatment of Indemnification Payments</U>. Any payments made to any party pursuant to this <U>ARTICLE XI</U> shall constitute an
adjustment of the Purchase Price for Tax purposes and shall be treated as such by Purchaser and
Seller on their Tax Returns to the extent permitted by applicable Law.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>ARTICLE XII<BR>
MISCELLANEOUS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">12.1 <U>Assignment; Binding Effect</U>. This Agreement shall be binding upon and inure to the benefit of the Parties hereto and
their respective successors and assigns; <I>provided</I>, <I>however</I>, that Purchaser may not sell, transfer,
assign, license, sublicense, delegate, pledge or otherwise dispose of, whether voluntarily,
involuntarily, by operation of Law or otherwise, this Agreement or any of its rights or obligations
under this Agreement (including by operation of law) without the prior written consent of Seller,
which consent may be granted, withheld or conditioned at Seller&#146;s sole and absolute discretion;
<I>provided, further, </I>that (a)&nbsp;as long as it would not cause any adverse Tax consequence to QLT Inc.
(or its successors or permitted assigns), Purchaser may freely, without the prior written consent
of Seller, sell, transfer, assign, license, sublicense, delegate, pledge or otherwise dispose of
this Agreement and any or all of its rights and obligations hereunder (i)&nbsp;to one or more of
Purchaser&#146;s Affiliates or (ii)&nbsp;to any third party in connection with any sale by Purchaser of all
or substantially all of its assets and (b)&nbsp;any permitted assignment shall preserve Seller&#146;s rights
under this Agreement. To the extent Seller makes a sale, transfer, assignment or other disposition
of this Agreement or any of its rights or obligations under this Agreement to a party outside the
United States without the prior written consent of Purchaser and such sale, transfer, assignment or
other disposition gives rise to a withholding tax obligation on the payments for Shares hereunder,
such withholding shall be permitted (notwithstanding Section&nbsp;9.4(f) or anything else in this
Agreement to the contrary); <I>provided, however</I>, that prior to making any such withholding, Purchaser
shall give Seller reasonable notice of its intention to withhold and the basis for such
withholding, and shall (both prior to and after such withholding) reasonably cooperate with Seller
in its efforts to eliminate or minimize such withholding obligations and/or to obtain credit for
payment thereof.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#091;*&#093; Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.
</DIV>

<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->37<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">12.2 <U>Expenses</U>. Except as otherwise specified herein, each Party shall bear its own expenses with respect
to the Transaction.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">12.3 <U>Notices</U>. All notices, requests, claims, demands and other communications hereunder shall be in
writing and shall be deemed to have been duly given (a)&nbsp;when received if delivered personally, (b)
when transmitted if telecopied (if confirmation of receipt is received), and (c)&nbsp;the day after it
is sent, if sent for next-day delivery to a domestic address by overnight mail or courier, to the
Parties at the following addresses:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">If to Seller, to:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 12%">QLT Inc.<br>
887 Great Northern Way<br>
Vancouver, BC<br>
Canada V5T 4T5<br>
Attention: Chief Executive Officer<br>
Facsimile: (604)&nbsp;707-7001<br>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 8%">with copies sent concurrently to (which shall by itself not constitute notice to
Seller for any purposes under this Agreement):
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 12%">Latham &#038; Watkins LLP<br>
140 Scott Drive<br>
Menlo Park, CA 94025<br>
Attention: Alan C. Mendelson, Esq.<br>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 0pt; margin-left: 20%">&nbsp;Ora T. Fisher, Esq.<br>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 0pt; margin-left: 12%">Facsimile: (650)&nbsp;463-2600
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 8%">If to Purchaser, to it at:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 12%">701 Centre Avenue<br>
Fort Collins, CO 80526<br>
Attention: Michael R. Duncan<br>
Facsimile: (970)&nbsp;482-1152<br>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 8%">with copies sent concurrently to (which shall by itself not constitute notice to
Purchaser for any purposes under this Agreement):
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 12%">Holme Roberts &#038; Owen LLP<br>
1700 Lincoln Street, Suite&nbsp;4100<br>
Denver, CO 80203<br>
Attention: Paul G. Thompson, Esq.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 0pt; margin-left: 20%">&nbsp;Troy R. Braegger, Esq.<br>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 0pt; margin-left: 12%">Facsimile: (303)&nbsp;866-0200
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>provided</I>, <I>however</I>, that if any Party shall have designated a different address by notice to the
others, then to the last address so designated.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#091;*&#093; Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->38<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">12.4 <U>Severability</U>. If any term, provision, covenant or restriction of this Agreement is held by a court of
competent jurisdiction or other Governmental Authority to be invalid, void, unenforceable or
against its regulatory policy such determination shall not affect the enforceability of any others
or of the remainder of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">12.5 <U>Entire Agreement</U>. This Agreement may not be amended, supplemented or otherwise modified except by an
instrument in writing signed by all of the Parties hereto. This Agreement, the Confidentiality
Agreement and the Other Transaction Documents contain the entire agreement of the Parties hereto
with respect to
the Transaction, superseding all negotiations, prior discussions and preliminary agreements
made prior to the date hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">12.6 <U>No Third Party Beneficiaries</U>. This Agreement is solely for the benefit of the Parties hereto, their respective Affiliates
and the Covered Parties and no provision of this Agreement shall be deemed to confer upon any third
party any remedy, claim, liability, reimbursement, claim of action or other right in excess of
those existing without reference to this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">12.7 <U>Waiver</U>. The failure of any Party to enforce any condition or part of this Agreement at any time
shall not be construed as a waiver of that condition or part, nor shall it forfeit any rights to
future enforcement thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">12.8 <U>Governing Law; Arbitration</U>. This Agreement (including any claim or controversy arising out of or relating to this
Agreement) shall be governed by the law of the State of New York without regard to conflict of law
principles that would result in the application of any Law other than the Law of the State of New
York. All Actions arising out of or relating to this Agreement shall be submitted to the AAA for
arbitration in accordance with its Commercial Arbitration Rules. The arbitration proceedings shall
be held in San Francisco, California before a single arbitrator to be chosen by the mutual
agreement of the Parties from a list of arbitrators provided by the AAA. If no mutual agreement is
reached, the arbitrator shall be selected by the AAA. The arbitrator so selected shall have
substantial experience in the pharmaceutical industry and be familiar with agreements of this type.
Each of the Parties agree to use its commercially reasonable efforts to cooperate with the
arbitrator, and such arbitrator shall be required to reach a determination regarding such dispute
no later than 180&nbsp;days after selection of such arbitrator. The decision of the arbitrator shall be
final, binding and conclusive on the Parties. The fees and expenses of the arbitrator shall be
shared equally by both Parties. Each Party shall initially bear its own costs and legal fees
associated with such arbitration, however, the prevailing Party in any such arbitration shall be
entitled to recover from the other Party the reasonable attorney&#146;s fees, costs and expenses
incurred by such prevailing Party in connection with such arbitration.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">12.9 <U>Waiver of Jury Trial</U>. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN
ANY LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED
HEREBY.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">12.10 <U>Injunctive Relief</U>. Notwithstanding anything to the contrary in this Agreement, either Seller or Purchaser will
have the right to seek injunctive relief in any court of competent jurisdiction as may be available
to such Party under the laws and rules applicable in such jurisdiction with respect to any matters
arising out of the other Party&#146;s performance of its obligations under this Agreement. Each Party
agrees that in the event the other Party institutes an appropriate Action seeking
injunctive/equitable relief for specific performance under this Agreement, the Party seeking such
relief shall not be required to provide the other Party with service of process of a complaint and
summons under the procedures set forth in any Canadian or other non-United States judicial process
or system. Under such circumstances, the Party seeking such relief need
only provide the other Party with two copies of a true, correct and lawfully issued summons
and complaint, via Federal Express (priority delivery).
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#091;*&#093; Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->39<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">12.11 <U>Headings</U>. The headings of the articles, sections and subsections of this Agreement are inserted for
convenience only and shall not be deemed to constitute a part hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">12.12 <U>Counterparts</U>. This Agreement may be executed manually or by facsimile by the Parties, in any number of
counterparts, all of which together shall be considered one and the same agreement and shall become
effective when a counterpart hereof shall have been signed by each of the Parties and delivered to
the other Parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">12.13 <U>Schedules</U>. Purchaser agrees that any disclosure by Seller in any Schedule attached hereto shall not
establish any threshold of materiality or concede the materiality of any matter or item disclosed.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">12.14 <U>Construction</U>. The language in all parts of this Agreement shall be construed, in all cases, according to
its fair meaning. The Parties acknowledge that each Party and its counsel have reviewed and
revised this Agreement and that any rule of construction to the effect that any ambiguities are to
be resolved against the drafting Party shall not be employed in the interpretation of this
Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">12.15 <U>Time of the Essence</U>. Time is of the essence with respect to the performance of this Agreement.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt">* * * * * * * * * * *
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#091;*&#093; Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->40<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed by their
respective duly authorized officers as of the date first above written.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>PURCHASER</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Michael R. Duncan
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Michael R. Duncan&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">Vice President&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>SELLER</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Robert L. Butchofsky
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Robert L. Butchofsky&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">President and Chief Executive Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">               /s/ Cameron Nelson
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Cameron Nelson&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">Vice President, Finance and<BR>
Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>
<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#091;*&#093; Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt">&#091;Redacted versions of exhibits and schedules have been filed with Canada SEDAR<BR>
(System for Electronic Document Analysis and Retrieval) on or about the date hereof.&#093;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#091;*&#093; Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
